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Abstract The intramolecular gold(I)-catalyzed [2+2+2] cycloaddition
of oxo-1,5-enynes bearing protected homopropargylic alcohols pro-
vides access to oxatricyclic adducts with good to excellent diastereose-
lectivity.
Key words gold, enynes, cycloisomerization, cycloaddition, Prins re-
action
The cycloisomerization of 1,n-enynes catalyzed by
gold(I) and other electrophilic metals is a powerful tool for
the construction of complex carbocycles and heterocycles,
including core scaffolds of biologically active natural prod-
ucts.1–3 We have reported that oxo-1,6-enynes react in the
presence of gold(I) complexes to give oxatricyclic com-
pounds through a formal [2+2+2] alkyne/alkene/carbonyl
cycloaddition process.4 The transformation presumably
proceeds by attack of the carbonyl on the cyclopropyl gold
carbene intermediate followed by Prins cyclization and de-
auration to afford the final oxatricyclic derivative.4 In a sim-
ilar vein, terminal alkynes and 5-oxoalkenes undergo a
[2+2+2] cycloaddition reaction by intermolecular cycliza-
tion of the alkyne and the alkene followed by intramolecu-
lar attack of the carbonyl group to form [3.2.1]oxabicy-
cles.5,6 Very recently, our group reported a similar transfor-
mation involving simple oxo-1,7-allenenes to afford
bicyclo[6.3.0]undecane ring systems.7 The related gold(I)-
catalyzed intermolecular reaction between allenamides
and oxoalkenes forms seven- to nine-membered rings.8
The synthetic potential of this [2+2+2]
alkyne/alkene/carbonyl cycloaddition has been exploited
for the synthesis of several oxygen-bridged sesquiter-
penoids, such as (+)-orientalol F (1)3a and (–)-englerin A
(2)3b,9 (Figure 1). We envisaged that other naturally occur-
ring compounds, such as isovelerenol (3)10 and bakkenolide
III (4)11 with an octahydro-1H-indene core (Figure 2) could
be accessed starting from adequately functionalized oxo-
1,5-enynes; however, examples involving those enynes are
scarce.1,12
Figure 1  Naturally occurring sesquiterpenes with a decahydro-4,8-ep-
oxyazulene structure
In a preliminary study, we found that (E)- and (Z)-
enynals 5 bearing a phenylsulfonyl group at the tether un-
dergo an analogous cycloaddition reaction cascade to form
related oxatricyclic adducts (Scheme 1).12 Surprisingly, the
cyclization of substrate (E)-5 was found to be poorly stereo-
selective yielding syn-6 and anti-6 in ratios that ranged
from 1:1.5 to 3–4:1, whereas good stereoselectivities were
achieved in the transformation of (Z)-5 into anti-6 (20–30:1
dr). We argued that these results could be explained if a
stepwise process was occurring through diastereomeric in-
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Figure 2  Naturally occurring sesquiterpenes with an octahydro-1H-in-
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attack of the carbonyl group by inversion or retention of the
configuration.12
Scheme 1  Gold(I)-catalyzed reaction of (E)- and (Z)-enynals 5
Therefore, we decided to study the stereoselectivity in
the reaction of other differently substituted substrates.
Herein, we wish to report our findings on the scope of the
cycloaddition cascade of O-protected homopropargylic and
allylic oxo-1,5-enynes. A theoretical study has also been
performed to support the mechanism of this transforma-
tion and to explain the overall stereoselectivity of this pro-
cess.
We first investigated the reaction of (Z)-6-methyl-9-
oxonon-5-en-1-yn-4-yl benzoate [(Z)-7a] as the model sub-
strate, using 5 mol% of commercially available cationic
JohnPhos–gold(I) catalyst A (Figure 3) at 25 °C in CH2Cl2.
Under these conditions, we observed complete conversion
of (Z)-7a to afford the cyclization product anti-8a in moder-
ate yield (Table 1, entry 1) together with decomposition
products. Various solvents were also evaluated in order to
find the optimum conditions (Table 1, entries 2–7). Where-
as no cycloisomerization was observed in THF, DME, DMSO,
DMF, MeCN or MeOH,13 the reaction proceeded in chlori-
nated or aromatic solvents. The best results were observed
in toluene (Table 1, entry 5) giving rise to anti-8a in higher
yield. Thus, toluene was selected for further optimization.
Efforts to improve this cyclization cascade using other gold
catalysts were unsuccessful (Table 1, entries 8–14). Al-
though the reaction proceeded well with gold catalyst E
(Table 1, entry 11), the use of sterically hindered phos-
phines resulted in a decrease in selectivity. To our delight,
decreasing the concentration from 0.1 to 0.01 M substan-
tially improved the reaction yield while maintaining the se-
lectivity (Table 1, entries 5, 15 and 16). Further studies re-
vealed that longer reaction times did not have any detri-
mental influence on the outcome of the transformation
(Table 1, entry 18; 88% yield, 91:9 dr), and that performing
the reaction at lower temperature did not improve the ste-
reoselectivity (Table 1, entry 17). Under the optimized con-
ditions, the cyclization of (Z)-7a led to the formation of
anti-8a in 90% isolated yield (92:8 dr). Additionally, the
configuration of the major isomer could be confirmed by X-
ray diffraction (Figure 4, anti-8a).
With optimized conditions in hand, we sought to evalu-
ate the generality of the reaction. Different (Z)- and (E)-
oxo-1,5-enynes bearing protected homopropargylic alco-
hols were prepared in four to six steps starting from com-
mercially available nerol and geraniol, respectively (see ex-
perimental section). In general, moderate to good yields
(38−90%) of the corresponding oxatricyclic adducts anti-
8a–j, syn-8a–e, syn-8g–i and syn-8k–l were obtained (Ta-
bles 2 and 3). Notably, the [2+2+2]-cycloaddition process
never occurred with complete stereoselectivity.
All the studied (Z)-1,5-enynes 7a–j cyclized with good
to high diastereoselectivities (Table 2). The sterics of the
substituent attached to the carbonyl group (R2 in Table 2)
did not seem to have a clear influence on the stereoselectiv-
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Table 1  Optimization of the Gold-Catalyzed Cyclization of (Z)-7a
Entry Cat. Solvent [M] Time 
(h)
Temp 
(°C)
Yield of 
anti-8a (%)a
Ratio 
anti/syn
 1 A CH2Cl2 0.1  3 25 55 93:7
 2 A DCE 0.1  3 25 46 91:9
 3 A CDCl3 0.1  3 25 62 91:9
 4 A benzene 0.1  3 25 64 89:11
 5 A toluene 0.1  3 25 66 92:8
 6 A PhCF3 0.1  3 25 41 (95)b 89:11
 7 A PhCl 0.1  3 25 36 88:12
 8 B toluene 0.1  2 25 29 (80)b 65:35
 9 C toluene 0.1  2 25 <1 (<5)b n.d.c
10 D toluene 0.1  2 25 32 (95)b 73:27
11 E toluene 0.1  2 25 66 81:19
12 F toluene 0.1  3 25 25 (90)b 68:32
13 G toluene 0.1  3 25 12 n.d.c
14 H toluene 0.1  3 25  6 (50)b n.d.c
15 A toluene 0.05  2 25 66 90:10
16d A toluene 0.01  6 25 83 92:8
17 A toluene 0.01 24  0 83 92:8
18 A toluene 0.01 15 25 88 91:9
a Determined by 1H NMR (mesitylene as internal standard).
b % of conversion, 100% if not stated otherwise.
c Not determined.
d Average yield of 3 runs.
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hol improved the overall diastereoselectivity of the formal
cycloaddition compared to the benzoate. The high stereose-
lectivities observed with (Z)-enynes are in agreement with
the previous observations for the related transformation
developed in our group.12 These oxatricycles were formed
in generally good yields and the major isomer can, in most
cases, be isolated in virtually diastereomerically pure form
by standard chromatographic methods or by crystallization.
This allowed us to obtain the crystal structures of three de-
rivatives, confirming that the major isomer formed in all
cases has the same relative configuration, regardless of the
nature of R1 and R2 (see Supporting Information, anti-8a,
anti-8b and anti-8g).14
Interestingly, the cyclization of (E)-enynals 7a,b and 7k,l
also proceeded with excellent stereoselectivity to give the
expected oxatricyclic products syn-8a,b and syn-8k,l in sat-
isfactory yields (Table 3, entries 1, 2, 9 and 10). Additionally,
other (E)-keto-1,5-enynes 7c–i were also examined. As
shown in Table 3, different trends were observed depending
on the nature of the protecting group. Thus, alkyl- [(E)-7d]
and aryl-substituted [(E)-7h] TBS-protected keto-1,5-
enynes led to the formation of cyclized derivatives (Table 3,
Figure 3  Gold catalysts
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Figure 4  ORTEP representations of the X-ray crystal structures of anti-
8a and syn-8c with 50% probability of the thermal ellipsoids
Table 2  Gold-Catalyzed Cyclization of (Z)-Oxo-enynesa
Entry Enyne R1 R2 Yield of anti-8 
(%)b
Ratio anti/syn
 1 (Z)-7a Bz H 82  97:3 (91:9)c
 2 (Z)-7b TBS H 58 ≥98:2 (83:17)c
 3 (Z)-7c Bz Me 79 (55)d  83:17 (83:17)c
 4 (Z)-7d TBS Me 70 >98:2 (>98:2)c
 5 (Z)-7e Bz c-Pr 74  89:11 (83:17)c
 6 (Z)-7f Bz c-Pent 68  85:15 (84:16)c
 7 (Z)-7g Bz Ph 88 (69)e  93:7 (91:9)c
 8 (Z)-7h TBS Ph 61e >98:2 (93:7)c
 9 (Z)-7i Bz C6H4CF3 65 >98:2 (87:13)c
10 (Z)-7j Bz 2-Npf 56e >98:2 (93:7)c
a [7] = 0.01 M.
b Product yields are reported after purification.
c Crude dr determined by NMR.
d Result of crystallization (dr ≥98:2).
e Result of crystallization (dr >98:2).
f 2-Np = 2-naphthyl.
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contrast, benzoate-protected 1,5-enynes bearing bulky
substituents on the ketone (Table 3, entries 5, 6 and 8) af-
forded the expected products, albeit with moderate yields
and a dramatic loss of selectivity. The relative configura-
tions of these compounds were assigned by analogy to that
of syn-8c, which was established by X-ray crystallography
(Figure 4, syn-8c).
Intriguingly, the treatment of 1,5-enyne (E)-7k with cat-
ionic JohnPhos–gold(I) catalyst A (3 mol%) in CH2Cl2 instead
of toluene at 23 °C led to the isolation of unexpected crown
ether 9, in low to moderate yield (Scheme 2). The structure
Table 3  Gold-Catalyzed Cyclization of (E)-Oxo-enynesa
Entry Enyne R1 R2 Yield of 
syn-8 (%)b
Ratio syn/anti
 1 (E)-7a Bz H 83  93:7 (93:7)e
 2 (E)-7b TBS H 82 >99:1 (99:1)e
 3c (E)-7c Bz Me 78  88:12 (89:11)e
 4 (E)-7d TBS Me 65  >99:1 (99:1)e
 5c (E)-7e Bz c-Pr 52  82:18 (87:13)e
 6c (E)-7g Bz Ph 38 (20)f  57:43 (58:42)e
 7 (E)-7h TBS Ph 90 >99:1 (96:4)e
 8 (E)-7i Bz C6H4CF3 48  91:9 (83:17)e
 9d (E)-7k MOM H 81 >99:1 (99:1)e
10 (E)-7l TES H 71 >99:1 (95:5)e
a [7] = 0.01 M.
b Product yields and dr are reported after purification.
c Reaction at 30 °C.
d Reaction at 40 °C.
e Crude dr determined by NMR.
f Result of crystallization (dr 56:44).
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Scheme 2  Gold(I)-catalyzed reaction of oxo-enyne (E)-7k to give 
crown ether 9
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Scheme 3  Proposed mechanism for the formation of oxatricyclic de-
rivatives syn-8 and anti-8 starting from enynals (E)-7
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ure 5). The formation of 9 can be rationalized by the bimo-
lecular reaction of two oxocarbenium intermediates 11′
(Scheme 3, R1 = R2 = H), in which the protecting group has
been cleaved under the conditions of the reaction.
We propose a mechanism for the formation of the oxa-
tricyclic derivative syn-8 starting from (E)-7 initiated by ac-
tivation of the alkyne to form a cyclopropyl gold(I)–carbene
10, followed by the intramolecular attack of the carbonyl
group to generate the oxocarbenium intermediate 11′
(Scheme 3). Intermediate 11′ could form a second C–C bond
through a Prins-type reaction with the alkenyl metal lead-
ing to carbene-like intermediate 12′, which is reminiscent
of the mechanism for the gold(I)-catalyzed reaction of oxo-
1,6-enynes.4 A final 1,2-H migration would lead to alkene–
gold(I) complex 13′ after deauration and, ultimately, to
product syn-8. The formation of the minor stereoisomer
anti-8 from (E)-7 is consistent with the existence of anoth-
er competitive stepwise process. Thus, the nucleophilic at-
tack of the carbonyl group on the opposite face of interme-
diate 10 would lead to isomer anti-8 through intermediates
11 and 12.
The mechanistic proposal outlined in Scheme 3 is sup-
ported by DFT calculations at the M06, 6-31G(d) (C, H, P, O)
and SDD (Au) levels, taking into account the solvent effect
(IEFPCM = toluene) and employing PMe3 as the phosphine
ligand (Figure 6). This study shows that the first cyclization
giving rise to intermediate II (corresponding to 10 in
Scheme 3) has the highest activation energy. It would thus
be the rate-determining step if the ligand exchange equilib-
rium that regenerates the entering reactive species I from
the final substrate–gold(I) complex is not considered. The
calculated energy differences for the two competitive tran-
sition states, TSII–III (ΔG# = 3.3 kcal·mol–1) and TSII–V (ΔG# =
9.5 kcal·mol–1), show that the formation of oxocarbenium
intermediate III is kinetically more favored than the forma-
tion of V, which is in general agreement with our experi-
mental findings. Furthermore, our calculations support the
Figure 6  Energy profiles for the competitive reaction pathways of gold(I) complex I. DFT calculations: M06, 6-31G(d) (C, H, P, O) and SDD (Au), IEFPCM 
(toluene). Values for free energies in kcal·mol–1.© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2016, 48, 3183–3198
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the 1,5-enyne,15 which undergoes intramolecular nucleo-
philic opening to form preferentially intermediate III by an
overall anti-type attack.
In summary, we have extended the scope of the intra-
molecular gold(I)-catalyzed formal [2+2+2] cycloaddition
reaction to O-protected homopropargylic and allylic oxo-
1,5-enynes. Under the optimized reaction conditions, the
cyclization of (Z)- and (E)-isomers takes place with moder-
ate to excellent yield (38–90%) and increased selectivity in
most of the cases, providing access to substituted octahy-
dro-1H-indenes. DFT calculations suggest that after the for-
mation of the cyclopropyl gold(I)–carbene, two competitive
pathways arising from the preferred face for the nucleophil-
ic attack of the carbonyl group are involved in this transfor-
mation and can explain the observed lack of complete ste-
reoselectivity. Investigations toward the synthesis of larger
ring systems to access other natural sesquiterpene motifs
are currently underway.
Reactions were performed under argon atmosphere in solvents dried
by passing through an activated alumina column on a PureSolv™ sol-
vent purification system (Innovative Technologies, Inc., MA). Thin-
layer chromatography was carried out using TLC aluminum sheets
coated with 0.2 mm of silica gel (Merck Gf234). Chromatographic pu-
rifications were carried out using flash grade silica gel (SDS Chro-
matogel 60 ACC, 40–60 μm). Melting points were determined using a
Büchi melting point apparatus. NMR spectra were recorded at 25 °C
on a Bruker Avance 300, 400 Ultrashield and Bruker Avance 500 Ul-
trashield apparatus. The data are reported as such: chemical shift (δ,
ppm) [multiplicity, coupling constant (Hz), integration]. The chemical
shifts are given in ppm downfield from tetramethylsilane using the
residual protiosolvent as internal reference. The abbreviations for
multiplicities are: s (singlet), d (doublet), t (triplet), q (quartet), quin
(quintet), sext (sextet), sept (septet). Mass spectra were recorded on a
Waters Micromass LCT Premier (ESI) instrument. Crystal structure
determinations were carried out using a Bruker-Nonius diffractome-
ter equipped with an APEX II 4K CCD area detector, an FR591 rotating
anode with MoKα radiation, Montel mirrors as the monochromator
and a Kryoflex low temperature device (T = –173 °C). Full-sphere data
collection was used with w and j scans. Programs used: data collec-
tion APEX-2, data reduction Bruker Saint V/.60A and absorption cor-
rection SADABS. Structure solution and refinement: crystal structure
solution was achieved using direct methods as implemented in
SHELXTL and visualized using the program XP. Missing atoms were
subsequently located from difference Fourier synthesis and added to
the atom list. Least-squares refinement on F2 using all measured in-
tensities was carried out using the program SHELXTL. All non-hydro-
gen atoms were refined including anisotropic displacement parame-
ters.
Allylic Homopropargylic Protected Alcohols S1; General Proce-
dure
(E)-6,10-Dimethylundeca-5,9-dien-1-yn-4-ol [(E)-S1] and (Z)-6,10-
dimethylundeca-5,9-dien-1-yn-4-ol [(Z)-S1] were prepared according
to known literature procedures.16 Spectroscopic data were in agree-
ment with those reported (see Supporting Information).
Preparation of Benzoic Esters of S1 (S2a)
In a dry round-bottom flask under argon, S1 (1 equiv) was dissolved
in pyridine (1 M solution) and the solution was cooled to 0 °C. Benzo-
yl chloride (1.1 equiv) was added slowly dropwise. The mixture was
stirred at 0 °C for 1 h after which time TLC indicated full conversion of
S1. The suspension was poured over 3–5% aq HCl (10 volumes of pyri-
dine) and extracted with Et2O (2 × volume HClaq). The combined ethe-
real extracts were washed with 3–5% aq HCl (5 × 1/2 initial volume
HClaq), the washed organic phase dried over Na2SO4 and the filtrate
concentrated. The crude material was purified by column chromatog-
raphy on silica gel eluting with pentane/Et2O (98:2 to 9:1) or cyclo-
hexane/EtOAc (95:5 to 9:1).
(E)-6,10-Dimethylundeca-5,9-dien-1-yn-4-yl Benzoate [(E)-S2a]
Prepared on 3 g scale from (E)-S1; the product was isolated as a pale
yellow oil (3.70 g, 80%).
1H NMR (400 MHz, CDCl3): δ = 8.08–8.03 (m, 2 H), 7.58–7.52 (m, 1 H),
7.46–7.40 (m, 2 H), 5.87 (dt, J = 9.1, 6.1 Hz, 1 H), 5.35 (dq, J = 9.1, 1.3
Hz, 1 H), 5.08 (tq, J = 5.4, 1.6 Hz, 1 H), 2.71–2.55 (m, 2 H), 2.16–2.02
(m, 4 H), 1.98 (t, J = 2.6 Hz, 1 H), 1.82 (d, J = 1.4 Hz, 3 H), 1.65 (d, J = 1.4
Hz, 3 H), 1.59 (app s, 3 H).
13C NMR (101 MHz, CDCl3): δ = 165.9, 142.3, 133.0, 131.9, 130.6,
129.8 (2 C), 128.4 (2 C), 123.8, 122.0, 79.9, 70.3, 69.7, 39.7, 26.4, 25.8,
25.3, 17.9, 17.2.
HRMS (ESI+): m/z [M + Na]+ calcd for C20H24O2Na: 319.1669; found:
319.1666.
(Z)-6,10-Dimethylundeca-5,9-dien-1-yn-4-yl Benzoate [(Z)-S2a]
Prepared on 2.5 g scale from (Z)-S1; the product was isolated as a pale
yellow oil (2.90 g, 84%).
1H NMR (500 MHz, CDCl3): δ = 8.09–8.04 (m, 2 H), 7.55 (ddt, J = 8.8,
7.0, 1.4 Hz, 1 H), 7.46–7.41 (m, 2 H), 5.88 (dt, J = 9.4, 5.9 Hz, 1 H), 5.40
(dd, J = 9.4, 1.6 Hz, 1 H), 5.14 (ddt, J = 7.1, 4.2, 1.6 Hz, 1 H), 2.63 (dd, J =
6.0, 2.7 Hz, 2 H), 2.42–2.33 (m, 1 H), 2.21–2.08 (m, 3 H), 2.00 (t, J = 2.6
Hz, 1 H), 1.79 (d, J = 1.4 Hz, 3 H), 1.67 (s, 3 H), 1.61 (s, 3 H).
13C NMR (126 MHz, CDCl3): δ = 165.8, 142.7, 133.0, 132.3, 130.7,
129.8 (2 C), 128.4 (2 C), 123.9, 122.6, 80.0, 70.4, 69.3, 32.9, 26.7, 25.8,
25.5, 23.6, 17.8.
HRMS (ESI+): m/z [M + Na]+ calcd for C20H24O2Na: 319.1669; found:
319.1673.
Preparation of the TBS Ether of S1 (S2b)
In a dry round-bottom flask under argon, S1 (1 equiv) was dissolved
in CH2Cl2 (0.3–0.6 M solution) and the solution was cooled to 0 °C.
Imidazole (1.8–2 equiv) and DMAP (ca. 1–5 mol%) were added fol-
lowed by the addition of TBSCl (1.5 equiv) [solid or as a solution in
CH2Cl2 (3.78 M)]. The mixture was then allowed to warm to 25 °C and
stirred for 2–6 h after which time TLC indicated full conversion of S1.
The suspension was poured on brine (3 volumes of CH2Cl2) and the
organic layer collected. The aq layer was re-extracted with CH2Cl2
(2 × 1/2 volume brine). The combined organic extracts were washed
with brine (1/2 initial volume brine), the washed organic phase dried
over Na2SO4 or MgSO4 and the filtrate concentrated. The crude mate-
rial was purified by column chromatography on silica gel eluting with
pentane/Et2O (100:0 to 95:5) or cyclohexane/EtOAc (95:5) to afford
the pure TBS ether.© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2016, 48, 3183–3198
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methylsilane [(E)-S2b]
Prepared on 1.5 g scale from (E)-S1; the product was isolated as a pale
yellow oil (2.24 g, 93%).
1H NMR (500 MHz, CDCl3): δ = 5.16 (dq, J = 8.7, 1.4 Hz, 1 H), 5.10 (ddq,
J = 8.4, 5.6, 1.4 Hz, 1 H), 4.53 (dt, J = 8.7, 6.4 Hz, 1 H), 2.38 (ddd, J =
16.5, 6.6, 2.7 Hz, 1 H), 2.27 (ddd, J = 16.5, 6.3, 2.7 Hz, 1 H), 2.09 (app q,
J = 7.3 Hz, 2 H), 2.03–1.98 (m, 2 H), 1.92 (t, J = 2.7 Hz, 1 H), 1.67 (s, 3
H), 1.66 (d, J = 1.3 Hz, 3 H), 1.60 (s, 3 H), 0.88 (s, 9 H), 0.06 (s, 3 H), 0.04
(s, 3 H).
13C NMR (126 MHz, CDCl3): δ = 136.4, 131.7, 128.0, 124.2, 82.0, 69.3,
68.6, 39.6, 28.7, 26.4, 26.0 (3 C), 25.8, 18.4, 17.8, 16.9, –4.2, –4.6.
HRMS (ESI+): m/z [M + Na]+ calcd for C19H34OSiNa: 329.2271; found:
329.2270.
(Z)-tert-Butyl[(6,10-dimethylundeca-5,9-dien-1-yn-4-yl)oxy]di-
methylsilane [(Z)-S2b]
Prepared on 2.5 g scale from (Z)-S1; the product was isolated as a pale
yellow oil (3.20 g, 83%).
1H NMR (400 MHz, CDCl3): δ = 5.16 (app d, J = 8.7 Hz, 1 H), 5.11 (app
tdd, J = 5.1, 2.8, 1.4 Hz, 1 H), 4.53 (ddd, J = 8.8, 6.7, 5.9 Hz, 1 H), 2.37
(ddd, J = 16.5, 6.7, 2.6 Hz, 1 H), 2.26 (ddd, J = 16.5, 5.9, 2.7 Hz, 1 H),
2.19–1.96 (m, 4 H), 1.93 (t, J = 2.6 Hz, 1 H), 1.71 (d, J = 1.4 Hz, 3 H),
1.69 (s, 3 H), 1.62 (s, 3 H), 0.88 (s, 9 H), 0.07 (s, 3 H), 0.03 (s, 3 H).
13C NMR (101 MHz, CDCl3): δ = 136.6, 132.1, 128.7, 124.2, 82.1, 69.4,
68.2, 32.7, 29.0, 26.7, 26.0 (3 C), 25.8, 23.2, 18.3, 17.8, –4.1, –4.5.
HRMS (ESI+): m/z [M + Na]+ calcd for C19H34OSiNa: 329.2271; found:
329.2268.
Preparation of the TES Ether of S1 (S2c)
In a dry round-bottom flask under argon, S1 (1 equiv) was dissolved
in CH2Cl2 (0.3 M solution) and the solution was cooled to 0 °C. Imidaz-
ole (2 equiv) and DMAP (1.11 equiv) were added followed by the ad-
dition of TESCl (1.5 equiv). The mixture was then allowed to warm to
25 °C and stirred for 1 h after which time TLC indicated full conver-
sion of S1. The suspension was poured on brine (3 volumes of CH2Cl2)
and the organic layer collected. The aq layer was re-extracted with
CH2Cl2 (2 × 1/2 volume brine). The combined organic extracts were
washed with brine (1/2 initial volume brine), the washed organic lay-
er dried over MgSO4 and the filtrate concentrated. The crude material
was purified by column chromatography on silica gel eluting with
pentane/Et2O (90:10).
(E)-[(6,10-Dimethylundeca-5,9-dien-1-yn-4-yl)oxy]triethylsilane 
[(E)-S2c]
Prepared on 579 mg scale from (E)-S1; the product was isolated as a
pale yellow oil (795 mg, 87%).
1H NMR (500 MHz, CDCl3): δ = 5.19 (dq, J = 8.7, 1.3 Hz, 1 H), 5.10 (ddq,
J = 8.4, 5.7, 1.4 Hz, 1 H), 4.53 (dt, J = 8.7, 6.4 Hz, 1 H), 2.41 (ddd, J =
16.5, 6.2, 2.7 Hz, 1 H), 2.29 (ddd, J = 16.5, 6.6, 2.7 Hz, 1 H), 2.13–2.06
(m, 2 H), 2.03–1.98 (m, 2 H), 1.92 (t, J = 2.6 Hz, 1 H), 1.68–1.66 (m, 6
H), 1.60 (s, 3 H), 0.95 (t, J = 7.9 Hz, 9 H), 0.59 (q, J = 7.9 Hz, 6 H).
13C NMR (126 MHz, CDCl3): δ = 136.7, 131.7, 127.8, 124.2, 81.8, 69.4,
68.2, 39.7, 28.8, 26.4, 25.8, 17.8, 16.9, 6.9 (3 C), 5.0 (3 C).
HRMS (ESI+): m/z [M + Na]+ calcd for C19H34OSiNa: 329.2271; found:
329.2272.
Preparation of the MOM Ether of S1 (S2d)
In a dry round-bottom flask under argon, S1 (1 equiv) was dissolved
in CH2Cl2 (0.3 M solution) and the solution was cooled to 0 °C. N,N-
Diisopropylethylamine (3 equiv) was added followed by the addition
of MOMCl (3 equiv). The mixture was then allowed to warm to 25 °C
and stirred for 2 h after which time TLC indicated full conversion of
S1. The suspension was poured on brine (3 volumes of CH2Cl2) and
the organic layer collected. The aq layer was re-extracted with CH2Cl2
(2 × 1/2 volume brine). The combined organic extracts were washed
with brine (1/2 initial volume brine), the washed organic phase dried
over MgSO4 and the filtrate concentrated. The crude material was pu-
rified by column chromatography on silica gel eluting with pen-
tane/Et2O (9:1 to 8:2).
(E)-4-(Methoxymethoxy)-6,10-dimethylundeca-5,9-dien-1-yne 
[(E)-S2d]
Prepared on 579 mg scale from (E)-S1; the product was isolated as a
pale yellow oil (657 mg, 93%).
1H NMR (400 MHz, CDCl3): δ = 5.13–5.04 (m, 2 H), 4.67 (d, J = 6.7 Hz, 1
H), 4.55–4.47 (m, 2 H), 3.39 (s, 3 H), 2.48 (ddd, J = 16.7, 6.5, 2.6 Hz, 1
H), 2.41 (ddd, J = 16.7, 5.9, 2.7 Hz, 1 H), 2.15–2.02 (m, 4 H), 1.98 (t, J =
2.6 Hz, 1 H), 1.70 (d, J = 1.4 Hz, 3 H), 1.67 (app d, J = 1.4 Hz, 3 H), 1.60
(s, 3 H).
13C NMR (101 MHz, CDCl3): δ = 141.7, 131.9, 124.0, 123.6, 93.4, 81.3,
69.9, 69.6, 55.5, 39.8, 26.4, 25.9, 25.8, 17.8, 16.8.
HRMS (ESI+): m/z [M + Na]+ calcd for C15H24O2Na: 259.1669; found:
259.1668.
Preparation of Aldehydes 7 from S2; General Procedure
In a dry round-bottom flask under argon, AD-mix-α (1.4 g per mmol
of S2) and methylsulfonamide (1 equiv) were dissolved in t-
BuOH/H2O (1:1) (15 mL per mmol of S2) and the solution was cooled
to 0 °C. S2 (1 equiv) was added slowly as a solution in t-BuOH (0.5 mL
per mmol). The mixture was stirred at 0 °C for 5 min then allowed to
warm to 25 °C and stirred for 16 h. TLC indicated full conversion of S2
into the diol. The suspension was quenched by addition of a sat. solu-
tion of Na2SO3 (15 mL per mmol) and then solid Na2SO3 (2 g per
mmol). The resulting mixture was stirred at 25 °C for 1 h, then poured
on brine (5 volumes of t-BuOH) and extracted with EtOAc (4 × volume
t-BuOH). The combined organic extracts were washed with a sat.
solution of Na2SO3 (15 mL per mmol) (2 × volume t-BuOH) and a sat.
solution of NaHCO3 (volume t-BuOH). The washed organic extracts
were dried over Na2SO4 and the filtrate concentrated. The crude diol
was redissolved in HPLC grade CH2Cl2 (20 mL per mmol) and the solu-
tion cooled to 0 °C and NaIO4@SiO217 (2 g per mmol) was added. The
suspension was stirred at 25 °C for 1.5–3 h after which time TLC indi-
cated full conversion of the diol. The solids were filtered off on a pad
of Celite and washed with Et2O (3 × 10 mL per mmol) and the filtrate
concentrated. The resulting crude aldehyde was purified by column
chromatography on silica gel eluting with pentane/Et2O (98:2 to 9:1)
or cyclohexane/EtOAc (90:10 to 80:20) to afford the pure aldehyde.
(E)-6-Methyl-9-oxonon-5-en-1-yn-4-yl Benzoate [(E)-7a]
Prepared on 2.63 g scale from (E)-S2a; the product was isolated as a
pale yellow oil (1.59 g, 66%).
1H NMR (400 MHz, CDCl3): δ = 9.77 (t, J = 1.7 Hz, 1 H), 8.07–8.02 (m, 2
H), 7.56 (ddt, J = 8.7, 6.9, 1.3 Hz, 1 H), 7.47–7.40 (m, 2 H), 5.84 (dt, J =
9.0, 6.1 Hz, 1 H), 5.38 (ddq, J = 9.1, 2.7, 1.4 Hz, 1 H), 2.70–2.55 (m, 4 H),
2.42–2.36 (m, 2 H), 1.99 (t, J = 2.7 Hz, 1 H), 1.85 (d, J = 1.3 Hz, 3 H).© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2016, 48, 3183–3198
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129.8 (2 C), 128.5 (2 C), 122.8, 79.5, 70.5, 69.4, 41.9, 31.7, 25.2, 17.4.
HRMS (ESI+): m/z [M + MeOH + Na]+ calcd for C18H22O4Na: 325.1410;
found: 325.1403.
(Z)-6-Methyl-9-oxonon-5-en-1-yn-4-yl Benzoate [(Z)-7a]
Prepared on 2.5 g scale from (Z)-S2a; the product was isolated as a
pale yellow solid (2.90 g, 84%).
Mp 33–35 °C (CH2Cl2/pentane).
1H NMR (500 MHz, CDCl3): δ = 9.81 (t, J = 1.2 Hz, 1 H), 8.06–8.02 (m, 2
H), 7.58–7.53 (m, 1 H), 7.46–7.41 (m, 2 H), 5.86 (dt, J = 9.4, 6.1 Hz, 1
H), 5.38 (app dd, J = 9.4, 1.5 Hz, 1 H), 2.70–2.53 (m, 6 H), 2.01 (t, J = 2.6
Hz, 1 H), 1.77 (d, J = 1.4 Hz, 3 H).
13C NMR (126 MHz, CDCl3): δ = 201.7, 165.8, 140.6, 133.1, 130.4,
129.8 (2 C), 128.5 (2 C), 123.9, 79.7, 70.7, 69.2, 42.3, 25.3, 25.1, 23.3.
HRMS (ESI+): m/z [M + Na]+ calcd for C17H18O3Na: 293.1148; found:
293.1154 (also observed: m/z [M + MeOH + Na] calcd for C18H22O4Na:
325.1410; found: 325.1423).
(E)-6-[(tert-Butyldimethylsilyl)oxy]-4-methylnon-4-en-8-ynal 
[(E)-7b]
Prepared on 2.24 g scale from (E)-S2b; the product was isolated as a
pale yellow oil (1.314 g, 64%).
1H NMR (400 MHz, CDCl3): δ = 9.78 (t, J = 1.8 Hz, 1 H), 5.19 (dq, J = 8.7,
1.3 Hz, 1 H), 4.52 (dt, J = 8.6, 6.5 Hz, 1 H), 2.58–2.51 (m, 2 H), 2.43–
2.31 (m, 3 H), 2.27 (ddd, J = 16.5, 6.7, 2.7 Hz, 1 H), 1.92 (t, J = 2.7 Hz, 1
H), 1.69 (d, J = 1.4 Hz, 3 H), 0.87 (s, 9 H), 0.06 (s, 3 H), 0.02 (s, 3 H).
13C NMR (101 MHz, CDCl3): δ = 202.1, 134.7, 128.8, 81.6, 69.6, 68.4,
42.0, 31.7, 28.6, 25.9 (3 C), 18.3, 17.1, –4.3, –4.6.
HRMS (ESI+): m/z [M + Na]+ calcd for C16H28O2SiNa: 303.1751; found:
303.1744.
(Z)-6-[(tert-Butyldimethylsilyl)oxy]-4-methylnon-4-en-8-ynal 
[(Z)-7b]
Prepared on 3.0 g scale from (Z)-S2b; the product was isolated as a
pale yellow oil (2.40 g, 87%).
1H NMR (500 MHz, CDCl3): δ = 9.80 (t, J = 1.5 Hz, 1 H), 5.20 (app dd, J =
8.8, 1.4 Hz, 1 H), 4.52 (ddd, J = 8.9, 6.9, 6.0 Hz, 1 H), 2.58–2.53 (m, 2 H),
2.51–2.44 (m, 1 H), 2.40 (ddd, J = 16.5, 6.0, 2.7 Hz, 1 H), 2.35–2.24 (m,
2 H), 1.93 (t, J = 2.6 Hz, 1 H), 1.70 (d, J = 1.4 Hz, 3 H), 0.86 (s, 9 H), 0.06
(s, 3 H), 0.02 (s, 3 H).
13C NMR (126 MHz, CDCl3): δ = 201.7, 134.6, 129.9, 81.8, 69.8, 68.0,
42.5, 28.9, 25.9 (3 C), 24.7, 23.0, 18.3, –4.2, –4.5.
HRMS (ESI+): m/z [M + Na]+ calcd for C16H28O2SiNa: 303.1751; found:
303.1752 (also observed: m/z [M + MeOH + Na] calcd for C17H32O3SiNa:
335.2013; found: 335.2025).
(E)-4-Methyl-6-[(triethylsilyl)oxy]non-4-en-8-ynal [(E)-7l]
Prepared on 790 mg scale from (E)-S2c; the product was isolated as a
pale yellow oil (506 mg, 70%).
1H NMR (500 MHz, CDCl3): δ = 9.78 (t, J = 1.7 Hz, 1 H), 5.24–5.19 (m, 1
H), 4.53 (ddd, J = 8.7, 7.0, 5.9 Hz, 1 H), 2.55 (ddd, J = 8.0, 6.9, 1.6 Hz, 2
H), 2.41 (ddd, J = 16.4, 5.9, 2.6 Hz, 1 H), 2.36–2.32 (m, 2 H), 2.29 (ddd,
J = 16.5, 7.1, 2.7 Hz, 1 H), 1.92 (t, J = 2.7 Hz, 1 H), 1.70 (d, J = 1.3 Hz, 3
H), 0.94 (t, J = 7.9 Hz, 9 H), 0.58 (q, J = 7.7 Hz, 6 H).
13C NMR (126 MHz, CDCl3): δ = 202.1, 134.9, 128.7, 81.4, 69.6, 68.0,
42.0, 31.7, 28.7, 17.2, 6.9 (3 C), 5.0 (3 C).
HRMS (ESI+): m/z [M + Na]+ calcd for C16H28O2SiNa: 303.1751; found:
303.1756.
(E)-6-(Methoxymethoxy)-4-methylnon-4-en-8-ynal [(E)-7k]
Prepared on 650 mg scale from (E)-S2d; the product was isolated as a
pale yellow oil (385 mg, 57%).
1H NMR (400 MHz, CDCl3): δ = 9.77 (t, J = 1.7 Hz, 1 H), 5.17–5.12 (m, 1
H), 4.62 (d, J = 6.8 Hz, 1 H), 4.55–4.46 (m, 2 H), 3.38 (s, 3 H), 2.60–2.53
(m, 2 H), 2.47 (ddd, J = 16.7, 6.2, 2.7 Hz, 1 H), 2.44–2.35 (m, 3 H), 1.98
(t, J = 2.6 Hz, 1 H), 1.73 (d, J = 1.4 Hz, 3 H).
13C NMR (101 MHz, CDCl3): δ = 201.9, 139.6, 124.5, 93.6, 80.9, 69.8,
69.8, 55.5, 42.0, 31.8, 25.7, 17.1.
HRMS (ESI+): m/z [M + Na]+ calcd for C12H18O3Na: 233.1148; found:
233.1158.
Ketones 7c–j; General Procedure
Depending on the polarity of the alcohol intermediate S3 (and the
ease of purification), one of the two following methods was used for
the preparation of ketones 7c–j.
Method A
In a dry flask under argon, the corresponding aldehyde 7a,b (1 equiv)
was dissolved in anhydrous THF (ca. 4 mL per mmol) and the solution
was cooled to –78 °C. A solution of Grignard reagent R–MgX (1.5
equiv) was added slowly at –78 °C. The mixture was stirred at –78 °C
for 1.5–3 h during which time a milky suspension was observed. The
suspension was quenched by addition of a sat. aq solution of NH4Cl
(ca. 5 mL per mmol) at –78 °C, then allowed to warm to 25 °C whilst
stirring vigorously. It was then poured on brine (70 mL per mmol)
and extracted with Et2O (3 × 40 mL per mmol). The combined ethere-
al extracts were dried over Na2SO4 and the filtrate concentrated. The
crude material was purified by column chromatography on silica gel
eluting with cyclohexane/EtOAc to afford the alcohol as a mixture of
diastereomers (the unreacted aldehyde can be recovered and recycled
at this stage).
The pure alcohol was redissolved in CH2Cl2 (ca. 10 mL per mmol) and
the solution cooled to 0 °C and NaHCO3 (5 equiv) and Dess–Martin
periodinane (1.2 equiv) were added sequentially. The mixture was
stirred at 0 °C for 1–2 h and then at 25 °C for 1–2 h after which time
TLC showed full conversion of the alcohol into the less polar ketone.
The mixture was either quenched by addition of a sat. solution of
Na2S2O3 and extracted with CH2Cl2 or diluted with pentane (2–
3 × volume CH2Cl2) and filtered. The resulting crude product was pu-
rified by chromatography on silica gel eluting with cyclohexane/EtOAc
to afford the title ketone.
Method B
In a dry flask under argon, the corresponding aldehyde 7a,b (1 equiv)
was dissolved in anhydrous THF (ca. 4 mL per mmol) and the solution
was cooled to –78 °C. A solution of Grignard reagent R–MgX (1.5
equiv) was added slowly at –78 °C. The mixture was stirred at –78 °C
for 1.5–3 h during which time a milky suspension was observed. The
suspension was quenched by addition of a sat. aq solution of NH4Cl
(ca. 5 mL per mmol) at –78 °C, then allowed to warm to 25 °C whilst
stirring vigorously. It was then poured on brine (70 mL per mmol)
and extracted with Et2O (3 × 40 mL per mmol). The combined ethere-
al extracts were dried over Na2SO4 and the filtrate concentrated. The
crude alcohol (containing the unreacted starting aldehyde) was redis-
solved in CH2Cl2 (ca. 10 mL per mmol) and the solution cooled to 0 °C
and NaHCO3 (5 equiv) and Dess–Martin periodinane (1.2 equiv) were© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2016, 48, 3183–3198
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at 25 °C for 1–2 h after which time TLC showed full conversion of the
alcohol into the less polar ketone. The mixture was either quenched
by addition of a sat. solution of Na2S2O3 and extracted with CH2Cl2 or
diluted with pentane (2–3 × volume CH2Cl2) and filtered. The result-
ing crude product was purified by chromatography on silica gel elut-
ing with cyclohexane/EtOAc to afford the title ketone (the unreacted
aldehyde can be recovered and recycled).
(E)-9-Hydroxy-6-methyldec-5-en-1-yn-4-yl Benzoate [(E)-S3c]
Prepared on 300 mg scale from (E)-7a according to method A and us-
ing a commercial solution of MeMgBr in Et2O (3 M). The product was
purified by silica gel column chromatography eluting with cyclohex-
ane/EtOAc (4:1 to 3:1) and obtained as a colorless oil (221 mg, 70%, ca.
1:1 dr). Note: in the proton assignments below ‘1 H + 1 H’ refers to a
signal accounting for one proton of each diastereomer; likewise, ‘1 C +
1 C’ refers to a signal accounting for one carbon of each diastereomer.
1H NMR (400 MHz, CDCl3): δ = 8.07–8.02 (m, 2 H + 2 H), 7.58–7.52 (m,
1 H + 1 H), 7.47–7.40 (m, 2 H + 2 H), 5.89–5.81 (m, 1 H + 1 H), 5.39
(app d quin, J = 9.0, 1.4 Hz, 1 H + 1 H), 3.80 (app sept, J = 5.7 Hz, 1 H +
1 H), 2.71–2.56 (m, 2 H + 2 H), 2.24–2.06 (m, 2 H + 2 H), 1.99 and 1.99
(two t, J = 2.5 Hz, 1 H + 1 H), 1.84 (s, 3 H + 3 H), 1.63–1.55 (m, 2 H + 2
H), 1.20 (d, J = 6.2 Hz, 3 H + 3 H).
13C NMR (101 MHz, CDCl3): δ = 165.9, 165.9, 142.4 (1 C + 1 C), 133.0 (1
C + 1 C), 130.7 (1 C + 1 C), 129.8 (2 C + 2 C), 128.5 (2 C + 2 C), 122.3,
122.3, 79.8, 79.8, 70.4, 70.4, 69.7, 69.7, 68.0, 67.9, 37.2, 37.2, 36.1,
36.0, 25.3 (1 C + 1 C), 23.7, 23.7, 17.2 (1 C + 1 C).
HRMS (ESI+): m/z [M + Na]+ calcd for C18H22O3Na: 309.1461; found:
309.1457.
(E)-6-Methyl-9-oxodec-5-en-1-yn-4-yl Benzoate [(E)-7c)]
Prepared on 221 mg scale from S3c according to method A. The prod-
uct was purified by silica gel column chromatography eluting with
cyclohexane/EtOAc (9:1 to 4:1) to afford a colorless oil (186 mg, 85%);
60% yield over 2 steps.
1H NMR (400 MHz, CDCl3): δ = 8.06–8.02 (m, 2 H), 7.55 (ddt, J = 8.0,
6.9, 1.4 Hz, 1 H), 7.48–7.40 (m, 2 H), 5.84 (dt, J = 9.0, 6.1 Hz, 1 H),
5.38–5.32 (m, 1 H), 2.69–2.53 (m, 4 H), 2.36–2.29 (m, 2 H), 2.15 (s, 3
H), 1.99 (t, J = 2.6 Hz, 1 H), 1.83 (d, J = 1.4 Hz, 3 H).
13C NMR (101 MHz, CDCl3): δ = 208.1, 165.8, 141.0, 133.1, 130.5,
129.8 (2 C), 128.5 (2 C), 122.4, 79.7, 70.4, 69.5, 41.9, 33.4, 30.1, 25.2,
17.4.
HRMS (ESI+): m/z [M + Na]+ calcd for C18H20O3Na: 307.1305; found:
307.1306.
(Z)-9-Hydroxy-6-methyldec-5-en-1-yn-4-yl Benzoate [(Z)-S3c]
Prepared on 300 mg scale from (Z)-7a according to method A and us-
ing a commercial solution of MeMgBr in Et2O (3 M). The product was
purified by silica gel column chromatography eluting with cyclohex-
ane/EtOAc (85:15 to 7:3) and obtained as a colorless oil (208 mg, 65%,
ca. 1.15:1 dr; 80% based on recovered starting material) (plus 55 mg
recovered aldehyde, 18%).
1H NMR (500 MHz, CDCl3): δ = 8.07–8.03 (m, 2 H major + 2 H minor),
7.58–7.52 (m, 1 H major + 1 H minor), 7.46–7.40 (m, 2 H major + 2 H
minor), 5.92 (app dt, J = 9.3, 6.1 Hz, 1 H major + 1 H minor), 5.38–5.32
(m, 1 H major + 1 H minor), 3.84–3.73 (m, 1 H major + 1 H minor),
2.70–2.56 (m, 2 H major + 2 H minor), 2.50 (dt, J = 13.6, 8.2 Hz, 1 H
major), 2.38 (ddd, J = 13.5, 10.0, 5.6 Hz, 1 H minor), 2.30 (ddd, J = 13.4,
9.8, 6.7 Hz, 1 H minor), 2.19 (ddd, J = 13.7, 8.0, 5.7 Hz, 1 H major), 2.00
and 2.00 (two t, J = 2.6 Hz, 1 H major + 1 H minor), 1.78 (d, J = 1.4 Hz, 3
H minor), 1.76 (d, J = 1.4 Hz, 3 H major), 1.66–1.50 (m, 2 H major + 2 H
minor), 1.20 (d, J = 6.2 Hz, 3 H minor), 1.19 (d, J = 6.2 Hz, 3 H major).
13C NMR (126 MHz, CDCl3): δ = 166.1, 165.9, 143.0, 142.1, 133.2,
133.1, 130.5, 130.4, 129.9 (2 C one diastereomer), 129.8 (2 C one dias-
tereomer), 128.5 (2 C one diastereomer), 128.4 (2 C one diastereo-
mer), 123.2, 122.6, 79.9, 79.8, 70.5, 70.5, 69.7, 69.3, 68.0, 66.6, 37.7,
36.9, 29.2, 28.5, 25.6, 25.4, 23.9, 23.7, 23.5, 23.2.
HRMS (ESI+): m/z [M + Na]+ calcd for C18H22O3Na: 309.1461; found:
309.1451.
(Z)-6-Methyl-9-oxodec-5-en-1-yn-4-yl Benzoate [(Z)-7c)]
Prepared on 190 mg scale from S3c according to method A. The prod-
uct was purified by silica gel column chromatography eluting with
cyclohexane/EtOAc (4:1) to afford a colorless oil (179 mg, 95%); 62%
yield over 2 steps (76% based on recovered starting material).
1H NMR (400 MHz, CDCl3): δ = 8.07–8.01 (m, 2 H), 7.58–7.51 (m, 1 H),
7.47–7.39 (m, 2 H), 5.85 (dt, J = 9.3, 6.1 Hz, 1 H), 5.39–5.33 (m, 1 H),
2.70–2.41 (m, 6 H), 2.14 (s, 3 H), 2.00 (t, J = 2.7 Hz, 1 H), 1.74 (d, J = 1.5
Hz, 3 H).
13C NMR (101 MHz, CDCl3): δ = 208.0, 165.7, 141.1, 133.0, 130.5,
129.8 (2 C), 128.4 (2 C), 123.5, 79.8, 70.5, 69.3, 42.0, 30.0, 26.8, 25.3,
23.3.
HRMS (ESI+): m/z [M + Na]+ calcd for C18H20O3Na: 307.1305; found:
307.1304.
(E)-7-[(tert-Butyldimethylsilyl)oxy]-5-methyldec-5-en-9-yn-2-ol 
[(E)-S3d]
Prepared on 500 mg scale from (E)-7b according to method A and us-
ing a commercial solution of MeMgBr in Et2O (3 M). The product was
purified by silica gel column chromatography eluting with cyclohex-
ane/EtOAc (95:5 to 9:1) and obtained as a colorless oil (470 mg, 89%,
ca. 1:1 dr). Note: in the proton assignments below ‘1 H + 1 H’ refers to
a signal accounting for one proton of each diastereomer; likewise, ‘1 C
+ 1 C’ refers to a signal accounting for one carbon of each diastereo-
mer.
1H NMR (500 MHz, CDCl3): δ = 5.20 (app d quin, J = 8.6, 1.3 Hz, 1 H + 1
H), 4.53 (app dt, J = 8.6, 6.5 Hz, 1 H + 1 H), 3.80 (app sext J = 6.4 Hz, 1
H + 1 H), 2.40 (app ddd, J = 16.5, 6.2, 2.6 Hz, 1 H + 1 H), 2.28 (app ddd,
J = 16.5, 6.7, 2.6 Hz, 1 H + 1 H), 2.15–2.02 (m, 2 H + 2 H), 1.92 and 1.91
(two t, J = 2.6 Hz, 1 H + 1 H), 1.69 (d, J = 1.4 Hz, 3 H one diastereomer)
and 1.68 (d, J = 1.4 Hz, 3 H other diastereomer), 1.64–1.50 (m, 2 H + 2
H), 1.20 (d, J = 0.6 Hz, 3 H one diastereomer) and 1.19 (d, J = 0.6 Hz, 3
H other diastereomer), 0.87 (s, 9 H + 9 H), 0.06 (s, 3 H + 3 H), 0.03 (s, 3
H + 3 H).
13C NMR (126 MHz, CDCl3): δ = 136.6, 136.4, 128.2 (1 C + 1 C), 81.8,
81.8, 69.5, 69.4, 68.4 (1 C + 1 C), 68.2, 67.8, 37.2, 37.2, 36.2, 35.9, 28.7,
28.7, 26.0 (3 C + 3 C), 23.6 (1 C + 1 C), 18.3 (1 C + 1 C), 17.0 (1 C + 1 C),
–4.2, –4.2, –4.6 (1 C + 1 C).
HRMS (ESI+): m/z [M + Na]+ calcd for C17H32O2SiNa: 319.2064; found:
319.2072.
(E)-7-[(tert-Butyldimethylsilyl)oxy]-5-methyldec-5-en-9-yn-2-one 
[(E)-7d)]
Prepared on 470 mg scale from (E)-S3d according to method A. The
product was purified by silica gel column chromatography eluting
with cyclohexane/EtOAc (9:1) to afford a colorless oil (338.7 mg,
73%); 65% yield over 2 steps.© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2016, 48, 3183–3198
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4.51 (dt, J = 8.6, 6.5 Hz, 1 H), 2.57–2.51 (m, 2 H), 2.38 (ddd, J = 16.5,
6.3, 2.6 Hz, 1 H), 2.30–2.22 (m, 3 H), 2.15 (s, 3 H), 1.91 (t, J = 2.6 Hz, 1
H), 1.67 (d, J = 1.3 Hz, 3 H), 0.87 (s, 9 H), 0.05 (s, 3 H), 0.02 (s, 3 H).
13C NMR (126 MHz, CDCl3): δ = 208.3, 135.3, 128.3, 81.7, 69.5, 68.4,
42.1, 33.3, 30.0, 28.7, 26.0 (3 C), 18.3, 17.2, –4.2, –4.6.
HRMS (ESI+): m/z [M + Na]+ calcd for C17H30O2SiNa: 317.1907; found:
317.1909.
(Z)-7-[(tert-Butyldimethylsilyl)oxy]-5-methyldec-5-en-9-yn-2-ol 
[(Z)-S3d]
Prepared on 300 mg scale from (Z)-7b according to method A and us-
ing a commercial solution of MeMgBr in Et2O (3 M). The product was
purified by silica gel column chromatography eluting with cyclohex-
ane/EtOAc (95:5 to 9:1) and obtained as a colorless oil (220 mg, 69%,
ca. 1.35:1 dr; 81% based on recovered starting material) (plus 45 mg
recovered aldehyde, 15%).
1H NMR (500 MHz, CDCl3): δ = 5.20–5.14 (m, 1 H major + 1 H minor),
4.59–4.52 (m, 1 H major + 1 H minor), 3.83–3.75 (m, 1 H major + 1 H
minor), 2.43–2.36 (m, 1 H major + 1 H minor), 2.32–2.19 (m, 2 H major
+ 2 H minor), 2.13–2.02 (m, 1 H major + 1 H minor), 1.94 and 1.93
(two t, J = 2.7 Hz, 1 H major + 1 H minor), 1.72 (d, J = 1.4 Hz, 3 H mi-
nor), 1.71 (d, J = 1.4 Hz, 3 H major), 1.59–1.51 (m, 2 H major + 2 H
minor), 1.21 and 1.21 (two d, J = 6.2 Hz, 3 H major + 3 H minor), 0.87
(s, 9 H minor), 0.87 (s, 9 H major), 0.06 (s, 3 H major + 3 H minor), 0.04
(s, 3 H minor), 0.03 (s, 3 H major).
13C NMR (126 MHz, CDCl3): δ = 136.7, 136.6, 128.8, 128.7, 82.1, 82.0,
69.7, 69.6, 68.3, 68.1, 68.0, 67.8, 37.7, 37.4, 29.0, 29.0, 28.9, 28.7, 26.0
(3 C major + 3 C minor), 23.9, 23.8, 23.3, 23.3, 18.3 (1 C major + 1 C
minor), –4.1 (1 C major + 1 C minor), –4.5, –4.5.
HRMS (ESI+): m/z [M + Na]+ calcd for C17H32O2SiNa: 319.2064; found:
319.2074.
(Z)-7-[(tert-Butyldimethylsilyl)oxy]-5-methyldec-5-en-9-yn-2-one 
[(Z)-7d]
Prepared on 205 mg scale from (Z)-S3d according to method A. The
product was purified by silica gel column chromatography eluting
with cyclohexane/EtOAc (95:5 to 9:1) to afford a colorless oil (193 mg,
93%); 65% yield over 2 steps (75% based on recovered starting materi-
al).
1H NMR (500 MHz, CDCl3): δ = 5.20–5.15 (m, 1 H), 4.52 (dt, J = 8.8, 6.4
Hz, 1 H), 2.53 (app t, J = 7.9 Hz, 2 H), 2.44–2.34 (m, 2 H), 2.30–2.23 (m,
2 H), 2.15 (s, 3 H), 1.92 (t, J = 2.6 Hz, 1 H), 1.68 (d, J = 1.4 Hz, 3 H), 0.86
(s, 9 H), 0.06 (s, 3 H), 0.02 (s, 3 H).
13C NMR (126 MHz, CDCl3): δ = 208.0, 135.2, 129.5, 81.9, 69.6, 68.0,
42.2, 30.1, 28.9, 26.4, 25.9 (3 C), 23.1, 18.3, –4.2, –4.5.
HRMS (ESI+): m/z [M + Na]+ calcd for C17H30O2SiNa: 317.1907; found:
317.1906.
(E)-9-Cyclopropyl-9-hydroxy-6-methylnon-5-en-1-yn-4-yl Benzo-
ate [(E)-S3e]
Prepared on 268 mg scale from (E)-7a according to method A and us-
ing a freshly prepared solution of c-C3H5MgBr in Et2O (~0.4 M). The
product was purified by silica gel column chromatography eluting
with cyclohexane/EtOAc (8:2) and obtained as a colorless oil (116 mg,
37%, ca. 1:1 dr). Note: in the proton assignments below ‘1 H + 1 H’
refers to a signal accounting for one proton of each diastereomer;
likewise, ‘1 C + 1 C’ refers to a signal accounting for one carbon of each
diastereomer.
1H NMR (400 MHz, CDCl3): δ = 8.07–8.02 (m, 2 H + 2 H), 7.55 (app t,
J = 7.2 Hz, 1 H + 1 H), 7.43 (app t, J = 7.8 Hz, 2 H + 2 H), 5.86 (app dtd,
J = 8.9, 6.1, 1.5 Hz, 1 H + 1 H), 5.39 (app d, J = 9.2 Hz, 1 H + 1 H), 2.85
(app quin, J = 6.4 Hz, 1 H + 1 H), 2.70–2.56 (m, 2 H + 2 H), 2.29–2.10
(m, 2 H + 2 H), 2.00–1.96 (m, 1 H + 1 H), 1.84 (s, 3 H + 3 H), 1.79–1.70
(m, 2 H + 2 H), 0.96–0.85 (m, 1 H + 1 H), 0.57–0.45 (m, 2 H + 2 H),
0.30–0.16 (m, 2 H + 2 H).
13C NMR (101 MHz, CDCl3): δ = 165.9, 165.9, 142.5, 142.4, 133.0 (1 C +
1 C), 130.6, 130.6, 129.8 (2 C + 2 C), 128.5 (2 C + 2 C), 122.1, 122.0,
79.8, 79.8, 76.5, 76.4, 70.4, 70.3, 69.7 (1 C + 1 C), 35.8, 35.8, 35.2, 35.1,
25.3, 25.3, 18.1, 18.1, 17.3, 17.3, 2.9, 2.9, 2.7, 2.7.
HRMS (ESI+): m/z [M + Na]+ calcd for C20H24O3Na: 335.1618; found:
335.1614.
(E)-9-Cyclopropyl-6-methyl-9-oxonon-5-en-1-yn-4-yl Benzoate 
[(E)-7e]
Prepared on 115 mg scale from (E)-S3e according to method A. The
product was purified by silica gel column chromatography eluting
with cyclohexane/EtOAc (8:2) to afford a colorless oil (84.3 mg, 73%);
27% yield over 2 steps.
1H NMR (500 MHz, CDCl3): δ = 8.07–8.02 (m, 2 H), 7.58–7.53 (m, 1 H),
7.46–7.41 (m, 2 H), 5.85 (dt, J = 9.1, 6.1 Hz, 1 H), 5.39–5.35 (m, 1 H),
2.72–2.67 (m, 2 H), 2.67–2.57 (m, 2 H), 2.36 (td, J = 7.7, 1.3 Hz, 2 H),
1.98 (t, J = 2.6 Hz, 1 H), 1.92 (tt, J = 7.8, 4.5 Hz, 1 H), 1.84 (d, J = 1.4 Hz,
3 H), 1.04–0.96 (m, 2 H), 0.90–0.80 (m, 2 H).
13C NMR (126 MHz, CDCl3): δ = 210.2, 165.9, 141.2, 133.1, 130.5,
129.8 (2 C), 128.5 (2 C), 122.3, 79.7, 70.4, 69.5, 41.8, 33.6, 25.2, 20.6,
17.4, 10.9, 10.9.
HRMS (ESI+): m/z [M + Na]+ calcd for C20H22O3Na: 333.1461; found:
333.1450.
(Z)-9-Cyclopropyl-9-hydroxy-6-methylnon-5-en-1-yn-4-yl Benzo-
ate [(Z)-S3e]
Prepared on 300 mg scale from (Z)-7a according to method A and us-
ing a freshly prepared solution of c-C3H5MgBr in Et2O (~0.4 M). The
product was purified by silica gel column chromatography eluting
with cyclohexane/EtOAc (9:1 to 3:1) and obtained as a colorless oil
(230 mg, 66%, ca. 4:3 dr; 80% based on recovered starting material)
(plus 51 mg recovered starting material, 17%).
1H NMR (500 MHz, CDCl3): δ = 8.07–8.02 (m, 2 H major + 2 H minor),
7.58–7.52 (m, 1 H major + 1 H minor), 7.46–7.40 (m, 2 H major + 2 H
minor), 5.96–5.89 (m, 1 H major + 1 H minor), 5.39–5.33 (m, 1 H major
+ 1 H minor), 2.92–2.82 (m, 1 H major + 1 H minor), 2.69–2.57 (m, 2 H
major + 2 H minor), 2.53 (dt, J = 13.5, 8.3 Hz, 1 H major), 2.50–2.33 (m,
2 H minor), 2.22 (ddd, J = 13.5, 8.5, 5.3 Hz, 1 H major), 2.00 and 1.99
(two t, J = 2.7 Hz, 1 H major + 1 H minor), 1.87–1.62 (m, 3 + 2 H major
+ 3 + 2 H minor), 0.95–0.86 (m, 1 H major + 1 H minor), 0.55–0.43 (m,
3 H major + 1 H minor), 0.31–0.23 (m, 1 H major + 1 H minor), 0.23–
0.17 (m, 1 H minor), 0.17–0.12 (m, 1 H minor).
13C NMR (126 MHz, CDCl3): δ = 166.1, 165.9, 143.2, 142.3, 133.1,
133.0, 130.6, 130.5, 129.9 (2 C one diastereomer), 129.8 (2 C one dias-
tereomer), 128.5 (2 C one diastereomer), 128.4 (2 C one diastereo-
mer), 123.1, 122.6, 80.0, 79.8, 76.3, 75.5, 70.5, 70.4, 69.7, 69.3, 35.6,
35.0, 29.0, 28.7, 25.6, 25.4, 23.5, 23.3, 18.1, 17.9, 2.8, 2.7, 2.7, 2.6.
HRMS (ESI+): m/z [M + Na]+ calcd for C20H24O3Na: 335.1618; found:
335.1620.© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2016, 48, 3183–3198
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[(Z)-7e]
Prepared on 215 mg scale from (Z)-S3e according to method A. The
product was purified by silica gel column chromatography eluting
with cyclohexane/EtOAc (9:1) to afford a colorless oil (184 mg, 86%);
57% yield over 2 steps (69% based on recovered starting material).
1H NMR (500 MHz, CDCl3): δ = 8.07–8.02 (m, 2 H), 7.57–7.52 (m, 1 H),
7.46–7.40 (m, 2 H), 5.86 (dt, J = 9.3, 6.0 Hz, 1 H), 5.40–5.35 (m, 1 H),
2.75 (ddd, J = 16.7, 9.7, 5.9 Hz, 1 H), 2.71–2.59 (m, 3 H), 2.56 (dddd, J =
13.7, 9.7, 5.9, 0.7 Hz, 1 H), 2.49 (dddd, J = 13.8, 9.7, 6.0, 0.8 Hz, 1 H),
2.00 (t, J = 2.7 Hz, 1 H), 1.93 (tt, J = 7.8, 4.6 Hz, 1 H), 1.76 (d, J = 1.4 Hz,
3 H), 1.04–1.00 (m, 2 H), 0.88–0.83 (m, 2 H).
13C NMR (126 MHz, CDCl3): δ = 210.1, 165.8, 141.3, 133.0, 130.5,
129.8 (2 C), 128.4 (2 C), 123.4, 79.9, 70.5, 69.3, 41.8, 27.0, 25.4, 23.4,
20.5, 10.9 (2 C).
HRMS (ESI+): m/z [M + Na]+ calcd for C20H22O3Na: 333.1461; found:
333.1458.
(Z)-9-Cyclopentyl-6-methyl-9-oxonon-5-en-1-yn-4-yl Benzoate 
[(Z)-7f]
Prepared on 300 mg scale from (Z)-7a according to method B and us-
ing a freshly prepared solution of c-C5H9MgBr in Et2O (~1.2 M). The
product was purified by silica gel column chromatography eluting
with cyclohexane/EtOAc (95:5 to 4:1) and isolated as a colorless oil
(109 mg, 29% over 2 steps; 75% based on recovered starting material)
(plus 184 mg of recovered aldehyde, 61%).
1H NMR (500 MHz, CDCl3): δ = 8.06–8.02 (m, 2 H), 7.54 (ddt, J = 8.8,
7.0, 1.4 Hz, 1 H), 7.45–7.40 (m, 2 H), 5.85 (dt, J = 9.3, 6.0 Hz, 1 H), 5.37
(dd, J = 9.2, 1.5 Hz, 1 H), 2.89–2.81 (m, 1 H), 2.68–2.41 (m, 6 H), 2.00
(t, J = 2.7 Hz, 1 H), 1.84–1.49 (m, 11 H).
13C NMR (126 MHz, CDCl3): δ = 212.4, 165.7, 141.5, 133.0, 130.6,
129.8 (2 C), 128.4 (2 C), 123.3, 79.9, 70.5, 69.3, 51.5, 40.1, 29.0, 29.0,
26.9, 26.1, 26.1, 25.3, 23.4.
HRMS (ESI+): m/z [M + Na]+ calcd for C22H26O3Na: 361.1774; found:
361.1767.
(E)-6-Methyl-9-oxo-9-phenylnon-5-en-1-yn-4-yl Benzoate [(E)-7g]
Prepared on 300 mg scale from (E)-7a according to method B and us-
ing a commercial solution of PhMgBr in Et2O (3 M). The product was
purified by silica gel column chromatography eluting with cyclohex-
ane/EtOAc (4:1 to 3:1) and isolated as a colorless oil (233 mg, 61%
over 2 steps).
1H NMR (300 MHz, CDCl3): δ = 8.10–8.03 (m, 2 H), 8.00–7.93 (m, 2 H),
7.61–7.53 (m, 2 H), 7.51–7.41 (m, 4 H), 5.89 (dt, J = 9.0, 6.1 Hz, 1 H),
5.43 (app dq, J = 9.1, 1.3 Hz, 1 H), 3.17–3.08 (m, 2 H), 2.64 (dt, J = 5.8,
2.5 Hz, 2 H), 2.56–2.47 (m, 2 H), 1.98 (t, J = 2.4 Hz, 1 H), 1.91 (s, 3 H).
13C NMR (126 MHz, CDCl3): δ = 199.6, 165.9, 141.3, 137.1, 133.2,
133.1, 130.5, 129.8 (2 C), 128.7 (2 C), 128.5 (2 C), 128.2 (2 C), 122.5,
79.7, 70.4, 69.5, 37.0, 33.9, 25.2, 17.5.
HRMS (ESI+): m/z [M + Na]+ calcd for C23H22O3Na: 369.1461; found:
369.1449.
(Z)-6-Methyl-9-oxo-9-phenylnon-5-en-1-yn-4-yl Benzoate [(Z)-7g]
Prepared on 300 mg scale from (Z)-7a according to method B and us-
ing a commercial solution of PhMgBr in Et2O (3 M). The product was
purified by silica gel column chromatography eluting with cyclohex-
ane/EtOAc (95:5 to 9:1) and isolated as a colorless solid (279 mg, 73%
over 2 steps).
Mp 40–43 °C.
1H NMR (500 MHz, CDCl3): δ = 8.07–8.02 (m, 2 H), 7.99–7.93 (m, 2 H),
7.58–7.51 (m, 2 H), 7.48–7.39 (m, 4 H), 5.88 (dt, J = 9.3, 6.0 Hz, 1 H),
5.41 (app d, J = 9.9 Hz, 1 H), 3.21 (ddd, J = 17.0, 9.6, 5.7 Hz, 1 H), 3.09
(ddd, J = 17.0, 9.7, 6.1 Hz, 1 H), 2.75–2.60 (m, 4 H), 2.00 (t, J = 2.6 Hz, 1
H), 1.82 (d, J = 1.4 Hz, 3 H).
13C NMR (126 MHz, CDCl3): δ = 199.6, 165.7, 141.3, 137.0, 133.1,
133.0, 130.5, 129.8 (2 C), 128.7 (2 C), 128.4 (2 C), 128.2 (2 C), 123.6,
79.9, 70.5, 69.4, 37.1, 27.3, 25.4, 23.5.
HRMS (ESI+): m/z [M + Na]+ calcd for C23H22O3Na: 369.1461; found:
369.1469.
(E)-6-[(tert-Butyldimethylsilyl)oxy]-4-methyl-1-phenylnon-4-en-
8-yn-1-one [(E)-7h]
Prepared on 309 mg scale from (E)-7b according to method B and us-
ing a commercial solution of PhMgBr in Et2O (3 M). The product was
purified by silica gel column chromatography eluting with cyclohex-
ane/EtOAc (4:1 to 3:1) and isolated as a colorless oil (201 mg, 51%
over 2 steps).
1H NMR (500 MHz, CDCl3): δ = 7.98–7.93 (m, 2 H), 7.59–7.54 (m, 1 H),
7.49–7.44 (m, 2 H), 5.21 (app dq, J = 8.6, 1.3 Hz, 1 H), 4.54 (dt, J = 8.6,
6.5 Hz, 1 H), 3.11–3.06 (m, 2 H), 2.46–2.41 (m, 2 H), 2.39 (ddd, J =
16.5, 6.5, 2.7 Hz, 1 H), 2.27 (ddd, J = 16.5, 6.4, 2.7 Hz, 1 H), 1.91 (t, J =
2.6 Hz, 1 H), 1.74 (d, J = 1.3 Hz, 3 H), 0.87 (s, 9 H), 0.07 (s, 3 H), 0.03 (s,
3 H).
13C NMR (126 MHz, CDCl3): δ = 199.7, 137.1, 135.5, 133.1, 128.7 (2 C),
128.4, 128.2 (2 C), 81.8, 69.5, 68.5, 37.1, 33.8, 28.7, 26.0 (3 C), 18.4,
17.3, –4.2, –4.6.
HRMS (ESI+): m/z [M + Na]+ calcd for C22H32O2SiNa: 379.2064; found:
369.2057.
(Z)-7-[(tert-Butyldimethylsilyl)oxy]-4-methyl-1-phenylnon-4-en-
8-yn-1-one [(Z)-7h]
Prepared on 300 mg scale from (Z)-7b according to method B and us-
ing a commercial solution of PhMgBr in Et2O (3 M). The product was
purified by silica gel column chromatography eluting with cyclohex-
ane/EtOAc (95:5 to 9:1) and isolated as a pale yellow oil (232 mg, 61%
over 2 steps) (plus 75 mg of recovered aldehyde, 25%; 81% based on
recovered starting material).
1H NMR (500 MHz, CDCl3): δ = 7.99–7.93 (m, 2 H), 7.60–7.54 (m, 1 H),
7.50–7.44 (m, 2 H), 5.25–5.20 (m, 1 H), 4.57 (dt, J = 8.8, 6.4 Hz, 1 H),
3.15–3.02 (m, 2 H), 2.65–2.57 (m, 1 H), 2.46–2.37 (m, 2 H), 2.30 (ddd,
J = 16.5, 6.7, 2.7 Hz, 1 H), 1.91 (t, J = 2.6 Hz, 1 H), 1.77 (d, J = 1.4 Hz, 3
H), 0.87 (s, 9 H), 0.07 (s, 3 H), 0.04 (s, 3 H).
13C NMR (126 MHz, CDCl3): δ = 199.6, 137.0, 135.5, 133.2, 129.6,
128.8 (2 C), 128.1 (2 C), 82.0, 69.7, 68.1, 37.3, 28.9, 26.9, 26.0 (3 C),
23.3, 18.3, –4.1, –4.5.
HRMS (ESI+): m/z [M + Na]+ calcd for C22H32O2SiNa: 379.2064; found:
379.2069.
(E)-6-Methyl-9-oxo-9-[4-(trifluoromethyl)phenyl]non-5-en-1-yn-
4-yl Benzoate [(E)-7i]
Prepared on 300 mg scale from (E)-7a according to method B and us-
ing a freshly prepared solution of 4-F3C-C6H4MgBr in Et2O (~0.8 M).
The product was purified by silica gel column chromatography elut-
ing with pentane/Et2O (95:5 to 9:1) and isolated as a pale yellow oil
(324 mg, 71% over 2 steps).© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2016, 48, 3183–3198
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7.59–7.53 (m, 1 H), 7.47–7.41 (m, 2 H), 5.86 (dt, J = 9.0, 6.1 Hz, 1 H),
5.40 (app dq, J = 9.1, 1.3 Hz, 1 H), 3.16–3.10 (m, 2 H), 2.69–2.57 (m, 2
H), 2.54–2.48 (m, 2 H), 1.97 (t, J = 2.6 Hz, 1 H), 1.89 (d, J = 1.3 Hz, 3 H).
13C NMR (126 MHz, CDCl3): δ = 198.6, 165.8, 140.8, 139.7 (app d, JC–F =
1.0 Hz), 134.5 (q, JC–F = 32.5 Hz), 133.1, 130.4, 129.8 (2 C), 128.5 (4 C),
125.8 (q, JC–F = 3.7 Hz, 2 C), 123.7 (q, JC–F = 273.4 Hz), 122.8, 79.6, 70.5,
69.5, 37.3, 33.6, 25.2, 17.5.
19F NMR (376 MHz, CDCl3): δ = –62.83.
HRMS (ESI+): m/z [M + Na]+ calcd for C24H21F3O3Na: 437.1335; found:
437.1333.
(Z)-6-Methyl-9-oxo-9-[4-(trifluoromethyl)phenyl]non-5-en-1-yn-
4-yl Benzoate [(Z)-7i]
Prepared on 300 mg scale from (Z)-7a according to method B and us-
ing a freshly prepared solution of 4-F3C-C6H4MgBr in Et2O (~0.8 M).
The product was purified by silica gel column chromatography elut-
ing with pentane/Et2O (95:5 to 9:1) and isolated as a pale yellow solid
(204 mg, 44% over 2 steps).
Mp 42–44 °C (pentane).
1H NMR (400 MHz, CDCl3): δ = 8.10–8.00 (m, 4 H), 7.71 (app d, J = 8.1
Hz, 2 H), 7.58–7.51 (m, 1 H), 7.46–7.38 (m, 2 H), 5.87 (dt, J = 9.4, 6.1
Hz, 1 H), 5.42 (app dd, J = 9.4, 1.5 Hz, 1 H), 3.26 (ddd, J = 17.2, 9.3, 6.0
Hz, 1 H), 3.09 (ddd, J = 17.2, 9.1, 6.7 Hz, 1 H), 2.75–2.59 (m, 4 H), 2.01
(t, J = 2.6 Hz, 1 H), 1.82 (d, J = 1.4 Hz, 3 H).
13C NMR (101 MHz, CDCl3): δ = 198.6, 165.8, 141.0, 139.6 (app d, JC–F =
1.1 Hz), 134.4 (q, JC–F = 32.6 Hz), 133.1, 130.4, 129.8 (2 C), 128.6 (2 C),
128.5 (2 C), 125.8 (q, JC–F = 3.7 Hz, 2 C), 123.9, 123.8 (q, JC–F = 272.7 Hz),
79.8, 70.6, 69.4, 37.4, 27.1, 25.3, 23.5.
19F NMR (376 MHz, CDCl3): δ = –63.19.
HRMS (ESI+): m/z [M + Na]+ calcd for C24H21O3F3Na: 437.1335; found:
437.1337.
(Z)-6-Methyl-9-(naphthalene-2-yl)-9-oxonon-5-en-1-yn-4-yl Ben-
zoate [(Z)-7j]
Prepared on 300 mg scale from (Z)-7b according to method B and us-
ing a freshly prepared solution of 2-naphthyl-MgBr in Et2O (~0.4 M).
The product was purified by silica gel column chromatography elut-
ing with cyclohexane/EtOAc (9:1 to 3:1) and isolated as a pale yellow
solid (269 mg, 61% over 2 steps).
Mp 74–77 °C.
1H NMR (500 MHz, CDCl3): δ = 8.52 (d, J = 1.7 Hz, 1 H), 8.08–8.02 (m, 3
H), 7.96 (d, J = 8.0 Hz, 1 H), 7.91–7.85 (m, 2 H), 7.60 (ddd, J = 8.2, 6.9,
1.4 Hz, 1 H), 7.57–7.51 (m, 2 H), 7.44–7.39 (m, 2 H), 5.93 (dt, J = 9.3,
6.1 Hz, 1 H), 5.44 (dd, J = 9.4, 1.6 Hz, 1 H), 3.37 (ddd, J = 16.7, 8.7, 6.7
Hz, 1 H), 3.21 (ddd, J = 16.7, 9.0, 6.9 Hz, 1 H), 2.74 (app ddd, J = 8.6, 6.5,
1.8 Hz, 2 H), 2.71–2.62 (m, 2 H), 2.01 (t, J = 2.6 Hz, 1 H), 1.86 (d, J = 1.4
Hz, 3 H).
13C NMR (126 MHz, CDCl3): δ = 199.6, 165.8, 141.4, 135.7, 134.3,
133.0, 132.7, 130.5, 130.0, 129.8 (2 C), 129.8, 128.6, 128.5, 128.5 (2 C),
127.9, 126.8, 124.0, 123.6, 79.9, 70.6, 69.5, 37.2, 27.6, 25.4, 23.6.
HRMS (ESI+): m/z [M + Na]+ calcd for C27H24O3Na: 419.1618; found:
419.1613.
Cyclization of Aldehydes and Ketones; General Procedure
A round-bottom flask was charged with the oxo-enyne substrate 7
and the flask was placed in a glovebox. In the glovebox, the substrate
was dissolved in toluene (0.01 M solution) and a stock solution of
[JohnPhosAu(NCMe)]SbF6 complex [5 mol% in CH2Cl2 (1/35 volume of
toluene)] was added in one portion to the vigorously stirred solution.
The resulting mixture was stirred at 25 °C for the indicated time. It
was then removed from the glovebox and quenched by addition of
QuadraPure™ resin (ca. 10 mg per 0.1 mmol) and the suspension
stirred vigorously for 15–60 min. It was then filtered on a sintered
funnel and the volatiles were removed in vacuo. The crude material
was redissolved in CDCl3 and the internal standard added to measure
the NMR yields and diastereomeric ratios. All the material was then
collected and purified according to the details provided for each com-
pound below.
(1S*,3aS*,4S*,7R*,7aS*)-7-Methyl-3a,4,5,6,7,7a-hexahydro-1H-4,7-
epoxyinden-1-yl Benzoate (syn-8a)
Performed on 0.21 mmol scale from (E)-7a (59 mg) with stirring for
16 h at 25 °C. Crude 1H NMR yield = 81% (83:8 dr, ca. 10:1). Purified by
preparative silica gel TLC eluting with cyclohexane/CH2Cl2/EtOAc
(80:15:5) and isolated as a pale yellow solid (48.8 mg, 0.181 mmol,
83%, 93:7 dr).
Mp 81–83 °C (pentane).
1H NMR (400 MHz, CDCl3): δ = 8.05–8.00 (m, 2 H), 7.58–7.52 (m, 1 H),
7.46–7.40 (m, 2 H), 6.07 (ddd, J = 5.7, 2.2, 1.0 Hz, 1 H), 5.92 (dtd, J =
5.7, 2.1, 0.6 Hz, 1 H), 5.77 (tt, J = 2.5, 1.2 Hz, 1 H), 4.58–4.53 (m, 1 H),
3.64–3.57 (m, 1 H), 2.55 (dddd, J = 9.2, 2.3, 1.4, 0.6 Hz, 1 H), 1.74–1.62
(m, 2 H), 1.61 (s, 3 H), 1.57–1.49 (m, 1 H), 1.45–1.35 (m, 1 H).
13C NMR (101 MHz, CDCl3): δ = 166.7, 139.9, 133.1, 130.9, 130.5,
129.8 (2 C), 128.5 (2 C), 85.8, 79.9, 78.9, 59.4, 56.2, 30.9, 28.5, 21.4.
HRMS (ESI+): m/z [M + Na]+ calcd for C17H18O3Na: 293.1148; found:
293.1151.
(1S*,3aS*,4R*,7S*,7aS*)-7-Methyl-3a,4,5,6,7,7a-hexahydro-1H-4,7-
epoxyinden-1-yl Benzoate (anti-8a)
Performed on 0.37 mmol scale from (Z)-7a (100 mg) with stirring for
6 h at 25 °C. Crude 1H NMR yield = 91% (91:9 dr, yield of combined
diastereomers). Purified by preparative silica gel TLC eluting with cy-
clohexane/CH2Cl2/EtOAc (80:15:5) and isolated as a pale yellow oil
(82 mg, 0.30 mmol, 82%, 97:3 dr). This compound was crystallized
from CH2Cl2/pentane to obtain single crystals suitable for X-ray dif-
fraction (see Supporting Information).
Mp 75–77 °C (CH2Cl2/pentane).
1H NMR (500 MHz, CDCl3): δ = 8.05–7.99 (m, 2 H), 7.54 (ddt, J = 7.9,
6.9, 1.3 Hz, 1 H), 7.45–7.39 (m, 2 H), 6.00 (ddd, J = 5.5, 2.2, 0.9 Hz, 1 H),
5.97–5.92 (m, 2 H), 4.19 (d, J = 5.1 Hz, 1 H), 3.15 (dq, J = 6.5, 2.1 Hz, 1
H), 2.32 (dd, J = 6.9, 1.7 Hz, 1 H), 1.87 (ddt, J = 12.9, 11.3, 5.4 Hz, 1 H),
1.68 (s, 3 H), 1.65–1.51 (m, 3 H).
13C NMR (126 MHz, CDCl3): δ = 166.3, 137.7, 133.0, 131.6, 130.6,
129.7 (2 C), 128.4 (2 C), 84.5, 81.9, 78.1, 57.5, 56.2, 36.5, 31.1, 18.4.
HRMS (ESI+): m/z [M + Na]+ calcd for C17H18O3Na: 293.1148; found:
293.1157.
tert-Butyldimethyl{[(1S*,3aS*,4S*,7R*,7aS*)-7-methyl-
3a,4,5,6,7,7a-hexahydro-1H-4,7-epoxyinden-1-yl]oxy}silane (syn-
8b)
Performed on 0.203 mmol scale from (E)-7b (57 mg) with stirring for
16 h at 25 °C. Crude 1H NMR yield = 82% (99:1 dr). Purified by silica
gel column chromatography eluting with cyclohexane/CH2Cl2/EtOAc
(80:15:5) and isolated as a pale yellow oil (47.7 mg, 0.170 mmol, 82%
>99:1 dr).© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2016, 48, 3183–3198
3195
P. Calleja et al. PaperSyn thesis1H NMR (500 MHz, CDCl3): δ = 5.81 (ddd, J = 5.6, 2.2, 0.9 Hz, 1 H), 5.71
(dt, J = 5.7, 2.0 Hz, 1 H), 4.62–4.59 (m, 1 H), 4.47 (t, J = 5.6 Hz, 1 H),
3.56–3.51 (m, 1 H), 2.35 (dt, J = 9.3, 1.7 Hz, 1 H), 1.64–1.53 (m, 1 H),
1.51 (s, 3 H), 1.49–1.41 (m, 2 H), 1.32–1.23 (m, 1 H), 0.88 (s, 9 H), 0.08
(s, 3 H), 0.08 (s, 3 H).
13C NMR (126 MHz, CDCl3): δ = 136.0, 134.8, 85.6, 79.1, 76.9, 62.6,
56.0, 30.8, 28.4, 26.1 (3 C), 21.7, 18.3, –4.1, –4.3.
HRMS (APCI+): m/z [M + H]+ calcd for C16H29O2Si: 281.1931; found:
281.1929.
tert-Butyldimethyl{[(1S*,3aS*,4R*,7S*,7aS*)-7-methyl-
3a,4,5,6,7,7a-hexahydro-1H-4,7-epoxyinden-1-yl]oxy}silane (anti-
8b)
Performed on 0.37 mmol scale from (Z)-7b (104 mg) by addition of
solid [JohnPhosAu(NCMe)SbF6] (5 mol%) to a toluene solution (0.01
M) of (Z)-7b, with stirring for 14 h at 25 °C. Crude 1H NMR yield = 73%
(83:17 dr, yield of combined diastereomers). Purified by silica gel col-
umn chromatography eluting with pentane/Et2O (95:5) and isolated
as a pale yellow oil (57 mg, 0.20 mmol, 58%, >98:2 dr) [minor diaste-
reomer syn-8b (12 mg) was also isolated, 12%].
1H NMR (400 MHz, CDCl3): δ = 5.76 (app s, 2 H), 4.80–4.76 (m, 1 H),
4.10 (d, J = 5.0 Hz, 1 H), 3.05 (dd, J = 6.9, 2.3 Hz, 1 H), 2.09 (dd, J = 6.9,
2.0 Hz, 1 H), 1.85–1.75 (m, 1 H), 1.63–1.46 (m, 6 H), 0.89 (s, 9 H), 0.10
(s, 3 H), 0.08 (s, 3 H).
13C NMR (101 MHz, CDCl3): δ = 135.8, 133.8, 84.3, 79.2, 78.6, 59.8,
57.3, 36.5, 31.2, 26.0 (3 C), 18.6, 18.2, –3.9, –4.3.
HRMS (ESI+): m/z [M + Na]+ calcd for C16H28O2SiNa: 303.1751; found:
303.1748.
(1S*,3aS*,4S*,7R*,7aS*)-1-(Methoxymethoxy)-7-methyl-
3a,4,5,6,7,7a-hexahydro-1H-4,7-epoxyindene (syn-8k)
Performed on 0.20 mmol scale from (E)-7k (42 mg) with stirring for
24 h at 40 °C. Crude 1H NMR yield = 82% (>99:1 dr). Purified by silica
gel column chromatography eluting with cyclohexane/CH2Cl2/EtOAc
(80:15:5) and isolated as a pale yellow oil (33.9 mg, 0.161 mmol, 81%,
>99:1 dr).
1H NMR (500 MHz, CDCl3): δ = 5.91 (ddd, J = 5.7, 2.2, 1.1 Hz, 1 H), 5.82
(dt, J = 5.7, 2.3 Hz, 1 H), 4.68–4.63 (m, 2 H), 4.51–4.47 (m, 2 H), 3.54–
3.48 (m, 1 H), 3.35 (s, 3 H), 2.43 (dt, J = 9.4, 1.9 Hz, 1 H), 1.64–1.57 (m,
1 H), 1.51 (s, 3 H), 1.50–1.43 (m, 2 H), 1.32–1.25 (m, 1 H).
13C NMR (126 MHz, CDCl3): δ = 137.9, 132.4, 95.3, 85.5, 81.4, 79.1,
59.7, 55.9, 55.3, 30.7, 28.4, 21.1.
HRMS (ESI+): m/z [M + Na]+ calcd for C12H18O3Na: 233.1148; found:
233.1143.
Triethyl{[(1S*,3aS*,4S*,7R*,7aS*)-7-methyl-3a,4,5,6,7,7a-hexahy-
dro-1H-4,7-epoxyinden-1-yl]oxy}silane (syn-8l)
Performed on 0.20 mmol scale from (E)-7l (56 mg) with stirring for
44 h at 25 °C. Crude 1H NMR yield = 84% (95:5 dr). Purified by silica
gel column chromatography eluting with cyclohexane/CH2Cl2/EtOAc
(80:15:5) and isolated as a pale yellow oil (39.7 mg, 0.142 mmol, 71%,
>99:1 dr).
1H NMR (500 MHz, CDCl3): δ = 5.83 (ddd, J = 5.6, 2.2, 0.9 Hz, 1 H), 5.72
(dtd, J = 5.7, 2.0, 0.6 Hz, 1 H), 4.58 (app tt, J = 2.3, 1.2 Hz, 1 H), 4.48 (t,
J = 5.7 Hz, 1 H), 3.58–3.52 (m, 1 H), 2.37 (d, J = 9.3 Hz, 1 H), 1.65–1.55
(m, 1 H), 1.52 (s, 3 H), 1.50–1.40 (m, 2 H), 1.33–1.26 (m, 1 H), 0.96 (t,
J = 7.9 Hz, 9 H), 0.61 (q, J = 7.9 Hz, 6 H).
13C NMR (101 MHz, CDCl3): δ = 136.2, 134.7, 85.6, 79.1, 76.5, 62.5,
55.9, 30.8, 28.5, 21.6, 6.9 (3 C), 5.0 (3 C).
HRMS (ESI+): m/z [M + Na]+ calcd for C16H28O2SiNa: 303.1751; found:
303.1751.
(1S*,3aS*,4S*,7R*,7aS*)-4,7-Dimethyl-3a,4,5,6,7,7a-hexahydro-1H-
4,7-epoxyinden-1-yl Benzoate (syn-8c)
Performed on 0.2 mmol scale from (E)-7c (56 mg) with stirring for 17
h at 30 °C. Crude 1H NMR yield = 87% (89:11 dr, yield of combined dia-
stereomers). Purified by preparative silica gel TLC eluting with cyclo-
hexane/CH2Cl2/EtOAc (80:15:5) and isolated as a pale yellow oil (44
mg, 0.154 mmol, 78%, 88:12 dr). Further purification by preparative
silica gel TLC eluting twice with cyclohexane/CH2Cl2/EtOAc (80:15:5)
resulted in the isolation of a pale yellow oil (20.2 mg, 0.071 mmol,
36%, >99:1 dr).
1H NMR (500 MHz, CDCl3): δ = 8.04–8.01 (m, 2 H), 7.56–7.52 (m, 1 H),
7.45–7.40 (m, 2 H), 6.06 (ddd, J = 5.6, 2.2, 1.0 Hz, 1 H), 5.92 (dtd, J =
5.6, 2.1, 0.6 Hz, 1 H), 5.77 (tt, J = 2.4, 1.2 Hz, 1 H), 3.28 (d quin, J = 9.2,
2.0 Hz, 1 H), 2.65 (dt, J = 9.3, 1.8 Hz, 1 H), 1.72–1.66 (m, 1 H), 1.64–
1.57 (m, 1 H), 1.56 (s, 3 H), 1.53 (ddd, J = 12.1, 3.4, 2.2 Hz, 1 H), 1.50 (s,
3 H), 1.48–1.43 (m, 1 H).
13C NMR (101 MHz, CDCl3): δ = 166.6, 139.7, 133.0, 130.8, 130.6,
129.7 (2 C), 128.4 (2 C), 85.9, 85.5, 80.5, 61.8, 60.5, 34.6, 32.6, 21.8,
21.6.
HRMS (ESI+): m/z [M + Na]+ calcd for C18H20O3Na: 307.1305; found:
307.1297.
(1S*,3aS*,4R*,7S*,7aS*)-4,7-Dimethyl-3a,4,5,6,7,7a-hexahydro-1H-
4,7-epoxyinden-1-yl Benzoate (anti-8c)
Performed on 0.25 mmol scale from (Z)-7c (71 mg) with stirring for
18 h at 25 °C. Crude 1H NMR yield = 89% (83:17 dr, yield of combined
diastereomers). Purified by column chromatography on silica gel elut-
ing with cyclohexane/CH2Cl2/EtOAc (80:15:5) and isolated as a pale
yellow solid (56 mg, 0.197 mmol, 79%, 83:17 dr). Further crystalliza-
tion from Et2O/pentane afforded 39 mg of a colorless solid (55%, ≥98:2
dr) (plus 17 mg of a pale yellow oil, 24%, 56:44 dr).
Mp 79–81 °C (Et2O/pentane).
1H NMR (500 MHz, CDCl3): δ = 8.05–8.00 (m, 2 H), 7.54 (ddt, J = 7.8,
6.9, 1.3 Hz, 1 H), 7.45–7.39 (m, 2 H), 6.02–5.98 (m, 2 H), 5.98–5.95 (m,
1 H), 3.13–3.08 (m, 1 H), 2.43 (dd, J = 6.8, 1.9 Hz, 1 H), 1.74–1.60 (m, 7
H), 1.38 (s, 3 H).
13C NMR (126 MHz, CDCl3): δ = 166.3, 136.5, 133.0, 132.2, 130.7,
129.7 (2 C), 128.4 (2 C), 84.3, 84.2, 82.1, 60.0, 57.7, 38.6, 38.1, 18.8,
18.5.
HRMS (ESI+): m/z [M + Na]+ calcd for C18H20O3Na: 307.1305; found:
307.1298.
tert-Butyl{[(1S*,3aS*,4S*,7R*,7aS*)-4,7-dimethyl-3a,4,5,6,7,7a-
hexahydro-1H-4,7-epoxyinden-1-yl]oxy}dimethylsilane (syn-8d)
Performed on 0.217 mmol scale from (E)-7d (64 mg) with stirring for
17 h at 25 °C. Crude 1H NMR yield = 97% (>99:1 dr). The product was
further purified by silica gel column chromatography eluting with cy-
clohexane/CH2Cl2/EtOAc (80:15:5) and isolated as a pale yellow oil
(41.4 mg, 0.141 mmol, 65%, >99:1 dr).
1H NMR (500 MHz, CDCl3): δ = 5.81 (ddd, J = 5.6, 2.2, 0.9 Hz, 1 H), 5.71
(dtd, J = 5.6, 2.0, 0.6 Hz, 1 H), 4.61–4.60 (m, 1 H), 3.22 (dd, J = 9.5, 2.0
Hz, 1 H), 2.46 (d, J = 9.4 Hz, 1 H), 1.55–1.50 (m, 2 H), 1.47 (s, 3 H), 1.45
(s, 3 H), 1.41–1.37 (m, 2 H), 0.88 (s, 9 H), 0.08 (s, 3 H), 0.08 (s, 3 H).© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2016, 48, 3183–3198
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61.6, 34.6, 32.5, 26.1 (3 C), 21.9, 21.8, 18.3, –4.1, –4.2.
HRMS (ESI+): m/z [M + Na]+ calcd for C17H30O2SiNa: 317.1907; found:
317.1896.
tert-Butyl{[(1S*,3aS*,4R*,7S*,7aS*)-4,7-dimethyl-3a,4,5,6,7,7a-
hexahydro-1H-4,7-epoxyinden-1-yl]oxy}dimethylsilane (anti-8d)
Performed on 0.3 mmol scale from (Z)-7d (88 mg) with stirring for 18
h at 25 °C. Crude 1H NMR yield = 74% (>98:2 dr). Purified by silica gel
column chromatography eluting with pentane/Et2O (95:5) and isolat-
ed as a pale yellow oil (62 mg, 0.211 mmol, 70%, >98:2 dr).
1H NMR (500 MHz, CDCl3): δ = 5.79 (dt, J = 5.7, 1.9 Hz, 1 H), 5.74 (ddd,
J = 5.7, 2.4, 1.2 Hz, 1 H), 4.80 (dq, J = 2.2, 1.1 Hz, 1 H), 3.00 (dq, J = 6.7,
2.0 Hz, 1 H), 2.18 (dd, J = 7.1, 2.2 Hz, 1 H), 1.71–1.53 (m, 4 H), 1.51 (s, 3
H), 1.31 (s, 3 H), 0.88 (s, 9 H), 0.09 (s 3 H), 0.08 (s, 3 H).
13C NMR (126 MHz, CDCl3): δ = 136.4, 132.5, 84.5, 84.1, 79.4, 61.4,
59.7, 38.5, 38.2, 26.0 (3 C), 18.9, 18.5, 18.2, –3.9, –4.3.
HRMS (ESI+): m/z [M + Na]+ calcd for C17H30O2SiNa: 317.1907; found:
317.1904.
(1S*,3aS*,4R*,7R*,7aS*)-4-Cyclopropyl-7-methyl-3a,4,5,6,7,7a-
hexahydro-1H-4,7-epoxyinden-1-yl Benzoate (syn-8e)
Performed on 0.2 mmol scale from (E)-7e (62 mg) with stirring for 15
h at 25 °C. Crude 1H NMR yield = 54% (80:20 dr, yield of combined di-
astereomers, 77% conversion). Purified by preparative silica gel TLC
eluting with cyclohexane/CH2Cl2/EtOAc (85:15:5) and isolated as a
pale yellow oil (32 mg, 0.103 mmol, 52%, 82:18 dr).
1H NMR (500 MHz, CDCl3): δ = 8.05–7.99 (m, 2 H + 2 H minor), 7.57–
7.51 (m, 1 H + 1 H minor), 7.45–7.40 (m, 2 H + 2 H minor), 6.05 (ddd,
J = 5.7, 2.1, 1.0 Hz, 1 H), 5.93–5.89 (m, 1 H), 5.76 (tt, J = 2.4, 1.2 Hz, 1
H), 3.30 (d quin, J = 9.0, 2.1 Hz, 1 H), 2.62 (dt, J = 9.3, 1.7 Hz, 1 H), 1.70–
1.62 (m, 1 H + 1 H minor), 1.54 (s, 3 H), 1.50–1.34 (m, 3 H + 3 H mi-
nor), 1.24–1.16 (m, 1 H), 0.60–0.52 (m, 2 H + 1 H minor), 0.53–0.46
(m, 1 H + 2 H minor), 0.45–0.37 (m, 1 H).
13C NMR (101 MHz, CDCl3): δ = 166.6, 140.3, 133.0, 130.7, 129.7 (2 C),
128.5 (2 C), 88.8, 84.9, 80.3, 60.1, 59.8, 31.8, 31.2, 21.6, 14.9, 1.5, 1.5; 1
C could not be detected due to overlap of signals.
HRMS (ESI+): m/z [M + Na]+ calcd for C20H22O3Na: 333.1461; found:
333.1464.
(1S*,3aS*,4S*,7S*,7aS*)-4-Cyclopropyl-7-methyl-3a,4,5,6,7,7a-
hexahydro-1H-4,7-epoxyinden-1-yl Benzoate (anti-8e)
Performed on 0.2 mmol scale from (Z)-7e (62 mg) with stirring for 18
h at 25 °C. Crude 1H NMR yield = 83% (87:13 dr, yield of combined
diastereomers). Purified by preparative silica gel TLC eluting with cy-
clohexane/CH2Cl2/EtOAc (85:12:3) and isolated as a pale yellow oil
(46 mg, 0.148 mmol, 74%, 89:11 dr).
1H NMR (500 MHz, CDCl3): δ = 8.05–8.00 (m, 2 H + 2 H minor), 7.57–
7.52 (m, 1 H + 1 H minor), 7.45–7.40 (m, 2 H + 2 H minor), 6.18 (app
dq, J = 4.9, 2.2 Hz, 1 H), 5.99–5.95 (m, 2 H), 3.22–3.18 (m, 1 H), 2.43
(dd, J = 6.9, 1.8 Hz, 1 H), 1.67 (ddd, J = 12.0, 9.2, 5.0 Hz, 1 H), 1.63–1.55
(m, 4 H + 3 H minor), 1.46 (td, J = 11.7, 4.9 Hz, 1 H + 2 H minor), 1.39
(ddd, J = 11.6, 9.2, 4.8 Hz, 1 H + 1 H minor), 1.08 (tt, J = 8.5, 5.4 Hz, 1
H), 0.60–0.54 (m, 1 H + 2 H minor), 0.53–0.49 (m, 2 H), 0.33–0.28 (m,
1 H).
13C NMR (126 MHz, CDCl3): δ = 166.3, 136.8, 133.0, 131.6, 130.7,
129.7 (2 C), 128.4 (2 C), 86.9, 83.7, 82.3, 60.6, 57.6, 37.6, 32.7, 18.7,
12.2, 2.2, 1.4.
HRMS (ESI+): m/z [M + Na]+ calcd for C20H22O3Na: 333.1461; found:
333.1461.
(1S*,3aS*,4S*,7S*,7aS*)-4-Cyclopentyl-7-methyl-3a,4,5,6,7,7a-
hexahydro-1H-4,7-epoxyinden-1-yl Benzoate (anti-8f)
Performed on 0.2 mmol scale from (Z)-7f (68 mg) with stirring for 18
h at 25 °C. Crude 1H NMR yield = 78% (84:16 dr, yield of combined di-
astereomers). Purified by preparative silica gel TLC eluting with cyclo-
hexane/CH2Cl2/EtOAc (85:12:3) and isolated as a pale yellow oil (46
mg, 0.136 mmol, 68%, 85:15 dr). Note: since the diastereomeric coun-
terpart of this tricycle was not prepared, the distinguishable data for
the minor diastereomer are also given below.
1H NMR (500 MHz, CDCl3): δ = 8.04–8.00 (m, 2 H + 2 H minor), 7.57–
7.51 (m, 1 H + 1 H minor), 7.45–7.39 (m, 2 H + 2 H minor), 6.07 (ddd,
J = 5.6, 2.2, 1.0 Hz, 1 H minor), 6.06–6.03 (m, 1 H), 6.00–5.95 (m, 2 H),
5.92–5.89 (m, 1 H minor), 5.76 (tt, J = 2.4, 1.2 Hz, 1 H minor), 3.40–
3.35 (m, 1 H minor), 3.19 (td, J = 4.2, 2.1 Hz, 1 H), 2.68 (dt, J = 9.2, 1.7
Hz, 1 H minor), 2.44 (dd, J = 6.9, 1.9 Hz, 1 H), 2.30 (app quin, J = 8.7 Hz,
1 H minor), 2.20 (quin, J = 8.1 Hz, 1 H), 1.86 (app ddq, J = 15.6, 8.0, 3.8
Hz, 1 H), 1.83–1.35 (m, 13 H + 13 H minor), 1.35–1.24 (m, 1 H + 2 H
minor).
13C NMR (126 MHz, CDCl3): δ = 166.3, 136.6, 132.9, 132.0, 130.7,
129.7 (2 C), 128.4 (2 C), 89.7, 83.8, 82.3, 60.0, 57.6, 41.0, 37.9, 30.1,
28.9, 27.5, 26.4, 26.2, 18.8. [Signals for syn-8f: 166.6, 141.0, 133.0,
130.6, 129.7, 91.0, 84.6, 80.2, 60.4, 59.3, 45.0, 32.1, 30.6, 28.3, 28.1,
26.0, 21.6.]
HRMS (ESI+): m/z [M + Na]+ calcd for C22H26O3Na: 361.1774; found:
361.1774.
(1S*,3aS*,4S*,7R*,7aS*)-7-Methyl-4-phenyl-3a,4,5,6,7,7a-hexahy-
dro-1H-4,7-epoxyinden-1-yl Benzoate (syn-8g)
Performed on 0.2 mmol scale from (E)-7g (64 mg) with stirring for 15
h at 30 °C. Crude 1H NMR yield = 72% (58:42 dr, yield of combined di-
astereomers). Purified by preparative silica gel TLC eluting with cyclo-
hexane/CH2Cl2/EtOAc (80:15:5) and isolated as an off-white solid
(26.1 mg, 0.075 mmol, 38%, 57:43 dr).
Mp 94–98 °C (pentane).
1H NMR (500 MHz, CDCl3): δ = 8.05–8.02 (m, 2 H + 2 H minor), 7.58–
7.53 (m, 1 H + 1 H minor), 7.45–7.41 (m, 3 H + 2 H minor), 7.39–7.35
(m, 2 H), 7.34–7.32 (m, 1 H + 4 H minor), 7.31–7.27 (m, 1 H), 6.24
(ddd, J = 5.6, 2.2, 1.0 Hz, 1 H), 6.03–6.00 (m, 1 H), 5.85 (d quin, J = 2.5,
1.2 Hz, 1 H), 3.59 (d quin, J = 9.2, 2.1 Hz, 1 H), 2.79 (dt, J = 9.4, 1.8 Hz, 1
H), 2.10–2.02 (m, 1 H), 1.88–1.77 (m, 2 H + 2 H minor), 1.68 (s, 3 H),
1.67–1.61 (m, 1 H).
13C NMR (101 MHz, CDCl3): δ = 166.7, 143.0, 139.8, 133.1, 131.4,
130.5, 129.8 (2 C), 128.5 (2 C), 128.5 (2 C), 127.4, 125.2 (2 C), 89.4,
85.7, 80.3, 63.2, 60.3, 35.0, 32.3, 21.7.
HRMS (ESI+): m/z [M + Na]+ calcd for C23H22O3Na: 369.1461; found:
369.1450.
(1S*,3aS*,4R*,7S*,7aS*)-7-Methyl-4-phenyl-3a,4,5,6,7,7a-hexahy-
dro-1H-4,7-epoxyinden-1-yl Benzoate (anti-8g)
Performed on 0.2 mmol scale from (Z)-7g (69 mg) with stirring for 14
h at 25 °C. Crude 1H NMR yield = 90% (91:9 dr, yield of combined dia-
stereomers). The product was purified by column chromatography on
silica gel eluting with cyclohexane/EtOAc (95:5) and isolated as a col-
orless solid (61 mg, 0.176 mmol, 88%, 93:7 dr). Further crystallization
from CH2Cl2 (200 μL) + Et2O (200 μL) + pentane (1 mL), first at 4 °C for
2 h then at –30 °C for 24 h, gave 30 mg of colorless needles (43%,© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2016, 48, 3183–3198
3197
P. Calleja et al. PaperSyn thesis>98:2 dr). The filtrate was recrystallized from CH2Cl2 (100 μL) + Et2O
(200 μL) + pentane (1.2 mL) to give a second crop of 18 mg of colorless
solid (26%, >98:2 dr). Overall yield after crystallization was 69%
(>98:2 dr).
Mp 137–138 °C (CH2Cl2/Et2O/pentane).
1H NMR (400 MHz, CDCl3): δ = 8.07–8.01 (m, 2 H), 7.58–7.52 (m, 1 H),
7.47–7.40 (m, 2 H), 7.37–7.30 (m, 4 H), 7.29–7.22 (m, 1 H), 6.06 (dt, J =
3.4, 1.7 Hz, 1 H), 5.89 (dt, J = 5.7, 2.1 Hz, 1 H), 5.45 (ddd, J = 5.7, 2.3, 1.2
Hz, 1 H), 3.52 (dq, J = 6.7, 2.2 Hz, 1 H), 2.55 (dd, J = 6.7, 1.8 Hz, 1 H),
2.24–2.15 (m, 1 H), 1.97–1.79 (m, 3 H), 1.77 (s, 3 H).
13C NMR (101 MHz, CDCl3): δ = 166.3, 140.9, 137.2, 133.0, 131.5,
130.6, 129.7 (2 C), 128.4 (2 C), 128.2 (2 C), 127.0, 125.4 (2 C), 87.9,
84.4, 82.3, 61.6, 57.4, 38.4, 38.2, 18.8.
HRMS (ESI+): m/z [M + Na]+ calcd for C23H22O3Na: 369.1461; found:
369.1459.
tert-Butyldimethyl{[(1S*,3aS*,4S*,7R*,7aS*)-7-methyl-4-phenyl-
3a,4,5,6,7,7a-hexahydro-1H-4,7-epoxyinden-1-yl]oxy}silane (syn-
8h)
Performed on 0.2 mmol scale from (E)-7h (71 mg) with stirring for 15
h at 25 °C. Crude 1H NMR yield = 98% (>96:4 dr). Purified by silica gel
column chromatography eluting with cyclohexane/CH2Cl2/EtOAc
(80:17:3 to 80:15:5) and isolated as a pale yellow oil (64.4 mg, 0.181
mmol, 90%, 99:1 dr).
1H NMR (400 MHz, CDCl3): δ = 7.44–7.39 (m, 2 H), 7.38–7.32 (m, 2 H),
7.29–7.24 (m, 1 H), 6.00 (ddd, J = 5.6, 2.2, 0.9 Hz, 1 H), 5.84–5.80 (m, 1
H), 4.70 (tt, J = 2.3, 1.2 Hz, 1 H), 3.54 (d quin, J = 9.4, 2.0 Hz, 1 H), 2.60
(dt, J = 9.4, 1.7 Hz, 1 H), 1.99 (app ddd, J = 12.4, 9.3, 4.1 Hz, 1 H), 1.76–
1.61 (m, 2 H), 1.61 (s, 3 H), 1.58–1.51 (m, 1 H), 0.91 (s, 9 H), 0.12 (s, 3
H), 0.11 (s, 3 H).
13C NMR (101 MHz, CDCl3): δ = 143.3, 136.0, 135.4, 128.4 (2 C), 127.2,
125.1 (2 C), 89.5, 85.4, 77.5, 63.6, 63.0, 35.1, 32.3, 26.1 (3 C), 22.0,
18.4, –4.1, –4.2.
HRMS (ESI+): m/z [M + Na]+ calcd for C22H32O2SiNa: 379.2064; found:
379.2071.
tert-Butyldimethyl{[(1S*,3aS*,4R*,7S*,7aS*)-7-methyl-4-phenyl-
3a,4,5,6,7,7a-hexahydro-1H-4,7-epoxyinden-1-yl]oxy}silane (anti-
8h)
Performed on 0.2 mmol scale from (Z)-7h (71 mg) with stirring for 18
h at 25 °C. Crude 1H NMR yield = 77% (>98:2 dr). Purified by silica gel
column chromatography eluting with pentane/Et2O (95:5) and isolat-
ed as an off-white solid (58 mg). Crystallization from hot pentane
gave analytically pure material (43.5 mg, 0.122 mmol, 61%, >98:2 dr).
Mp 72–75 °C (pentane).
1H NMR (500 MHz, CDCl3): δ = 7.35–7.27 (m, 4 H), 7.26–7.19 (m, 1 H),
5.68 (dt, J = 5.7, 2.0 Hz, 1 H), 5.21 (ddd, J = 5.7, 2.4, 1.2 Hz, 1 H), 4.91
(dq, J = 3.3, 1.9, 1.2 Hz, 1 H), 3.43 (dq, J = 6.8, 2.2 Hz, 1 H), 2.31 (dd, J =
7.0, 2.0 Hz, 1 H), 2.14 (ddd, J = 10.6, 8.6, 3.9 Hz, 1 H), 1.89–1.72 (m, 3
H), 1.64 (s, 3 H), 0.90 (s, 9 H), 0.12 (s, 3 H), 0.10 (s, 3 H).
13C NMR (126 MHz, CDCl3): δ = 141.2, 135.7, 133.2, 128.2 (2 C), 126.8,
125.4 (2 C), 88.2, 84.3, 79.6, 61.3, 61.1, 38.5, 38.4, 26.1 (3 C), 19.0,
18.2, –3.9, –4.2.
HRMS (ESI+): m/z [M + Na]+ calcd for C22H32O2SiNa: 379.2064; found:
379.2067.
(1S*,3aS*,4S*,7R*,7aS*)-7-Methyl-4-[4-(trifluoromethyl)phenyl]-
3a,4,5,6,7,7a-hexahydro-1H-4,7-epoxyinden-1-yl Benzoate (syn-8i)
Performed on 0.2 mmol scale from (E)-7i (82 mg) with stirring for 17
h at 25 °C. Crude 1H NMR yield = 78% (83:17 dr, yield of combined
diastereomers). Purified by preparative silica gel TLC eluting with cy-
clohexane/CH2Cl2/EtOAc (85:15:5) and isolated as a pale yellow oil
(39.6 mg, 0.096 mmol, 48%, 91:9 dr).
1H NMR (400 MHz, CDCl3): δ = 8.06–8.01 (m, 2 H + 2 H minor), 7.66–
7.60 (m, 2 H + 2 H minor), 7.59–7.52 (m, 3 H + 1 H minor), 7.47–7.40
(m, 2 H + 4 H minor), 6.23 (ddd, J = 5.7, 2.1, 1.0 Hz, 1 H), 6.05 (dt, J =
5.6, 2.1 Hz, 1 H), 5.85 (sept, J = 1.3 Hz, 1 H), 3.54 (d quin, J = 8.8, 2.2 Hz,
1 H), 2.80 (dt, J = 9.2, 1.7 Hz, 1 H), 2.13–2.04 (m, 1 H), 1.90–1.81 (m, 1
H + 3 H minor), 1.80–1.64 (m, 5 H + 3 H minor).
13C NMR (101 MHz, CDCl3): δ = 166.6, 147.0 (app d, JC–F = 1.1 Hz),
139.2, 133.2, 132.0, 130.4, 129.8 (2 C), 129.6 (q, JC–F = 32.4 Hz), 128.5
(2 C), 125.5 (q, JC–F = 4.0 Hz, 2 C), 125.5 (2 C), 124.3 (q, JC–F = 271.9 Hz),
89.0, 86.0, 80.1, 63.2, 60.4, 34.9, 32.3, 21.6.
19F NMR (376 MHz, CDCl3): δ = 62.55.
HRMS (ESI+): m/z [M + Na]+ calcd for C24H21O3F3Na: 437.1335; found:
437.1342.
(1S*,3aS*,4R*,7S*,7aS*)-7-Methyl-4-[4-(trifluoromethyl)phenyl]-
3a,4,5,6,7,7a-hexahydro-1H-4,7-epoxyinden-1-yl Benzoate (anti-
8i)
Performed on 0.2 mmol scale from (Z)-7i (100 mg) with stirring for
17 h at 25 °C. Crude 1H NMR yield = 99% (86:14 dr, yield of combined
diastereomers). Purified by preparative silica gel TLC eluting with cy-
clohexane/CH2Cl2/EtOAc (85:12:3) and isolated as a colorless solid (54
mg, 0.13 mmol, 65% >98:2 dr) (22 mg of a fraction containing a 57:43
dr mixture of diastereomers was also collected, 27%).
Mp 108–110 °C.
1H NMR (400 MHz, CDCl3): δ = 8.06–8.01 (m, 2 H), 7.60 (app d, J = 8.2
Hz, 2 H), 7.55 (ddt, J = 8.7, 6.9, 1.4 Hz, 1 H), 7.48–7.40 (m, 4 H), 6.05
(app dt, J = 3.2, 1.8 Hz, 1 H), 5.91 (dt, J = 5.7, 2.1 Hz, 1 H), 5.38 (ddd, J =
5.7, 2.3, 1.2 Hz, 1 H), 3.53 (dq, J = 6.7, 2.2 Hz, 1 H), 2.58 (dd, J = 6.8, 1.8
Hz, 1 H), 2.25–2.17 (m, 1 H), 1.94–1.80 (m, 3 H), 1.77 (s, 3 H).
13C NMR (101 MHz, CDCl3): δ = 166.3, 144.9 (app d, JC–F = 1.1 Hz),
136.4, 133.1, 132.1, 130.6, 129.7 (2 C), 129.3 (q, JC–F = 32.3 Hz), 128.5
(2 C), 125.9 (2 C), 125.2 (q, JC–F = 3.8 Hz, 2 C), 124.4 (q, JC–F = 271.9 Hz),
87.6, 84.8, 82.1, 61.6, 57.6, 38.3, 38.1, 18.7.
19F NMR (376 MHz, CDCl3): δ = –62.53.
HRMS (ESI+): m/z [M + Na]+ calcd for C24H21O3F3Na: 437.1335; found:
437.1338.
(1S*,3aS*,4R*,7S*,7aS*)-7-Methyl-4-(naphthalen-2-yl)-
3a,4,5,6,7,7a-hexahydro-1H-4,7-epoxyinden-1-yl Benzoate (anti-
8j)
Performed on 0.2 mmol scale from (Z)-7j (79 mg) with stirring for 17
h at 25 °C. Crude 1H NMR yield = 78% (94:6 dr). Purified by prepara-
tive silica gel TLC eluting with cyclohexane/CH2Cl2/EtOAc (85:12:3)
and isolated as a pale yellow oil that solidified on standing. Further
crystallization from CH2Cl2 (200 μL) + Et2O (200 μL) + pentane (1.2
mL), first at 4 °C for 2 h then at –30 °C for 16 h, gave 33 mg of a color-
less solid (42%, >98:2 dr). The filtrate was recrystallized from CH2Cl2
(100 μL) + Et2O (100 μL) + pentane (0.8 mL) to give a second crop of 11
mg of colorless solid (14%, >98:2 dr). Overall yield after crystallization
was 56% (>98:2 dr).
Mp 125–126 °C (CH2Cl2/Et2O/pentane).© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2016, 48, 3183–3198
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7.59–7.53 (m, 1 H), 7.52–7.40 (m, 5 H), 6.14–6.09 (m, 1 H), 5.90 (dt, J =
5.7, 2.1 Hz, 1 H), 5.44 (ddd, J = 5.8, 2.1, 1.1 Hz, 1 H), 3.62 (dq, J = 6.7,
2.2 Hz, 1 H), 2.61 (dd, J = 6.7, 1.8 Hz, 1 H), 2.30 (ddd, J = 11.3, 8.5, 4.9
Hz, 1 H), 1.99 (td, J = 11.7, 5.1 Hz, 1 H), 1.95–1.85 (m, 2 H), 1.83 (s, 3
H).
13C NMR (101 MHz, CDCl3): δ = 166.3, 138.4, 137.2, 133.3, 133.0,
132.6, 131.6, 130.7, 129.7 (2 C), 128.5 (2 C), 128.2, 128.0, 127.8, 126.2,
125.8, 123.9, 123.8, 88.1, 84.6, 82.3, 61.6, 57.6, 38.5, 38.4, 18.9.
HRMS (ESI+): m/z [M + Na]+ calcd for C27H24O3Na: 419.1618; found:
419.1614.
Crown Ether 9
A solution of (E)-7k (20 mg, 0.1mmol) and [JohnPhosAu(NCMe)]SbF6
complex (3 mol%) in anhydrous CH2Cl2 (1 mL) was stirred at 0 °C for
10 h. It was then quenched by addition of Et3N (5 μL) and the solvent
was removed in vacuo (at 25 °C). The crude material was purified by
silica gel column chromatography eluting with cyclohexane/EtOAc
(90:10) and isolated as a white solid (8.1 mg, 0.024 mmol, 49%). Note:
the reaction was performed under an air atmosphere.
Mp 258–260 °C.
1H NMR (500 MHz, CDCl3): δ = 5.83–5.79 (m, 2 H), 5.63 (app ddd, J =
5.6, 4.3, 2.5 Hz, 2 H), 5.33 (dd, J = 6.1, 2.6 Hz, 2 H), 4.72 (d, J = 6.0 Hz, 2
H), 3.27 (app q, J = 2.1 Hz, 2 H), 2.63 (ddt, J = 17.8, 8.2, 2.2 Hz, 2 H),
2.35 (dt, J = 17.9, 2.1 Hz, 2 H), 2.28–2.19 (m, 2 H), 2.13–2.07 (m, 2 H),
2.06–1.98 (m, 2 H), 1.64–1.54 (m, 2 H), 1.02 (s, 6 H).
13C NMR (126 MHz, CDCl3): δ = 131.1 (2 C), 130.6 (2 C), 102.4 (2 C),
85.3 (2 C), 76.1 (2 C), 63.6 (2 C), 40.6 (2 C), 36.6 (2 C), 33.1 (2 C), 22.2
(2 C).
HRMS (ESI+): m/z [M + Na]+ calcd for C20H28O4Na: 355.1880; found:
355.1868.
This compound was crystallized from CHCl3 to obtain single crystals
suitable for X-ray diffraction (see Supporting Information).
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